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I. Summary 
Background: Specific oncogenic types of human papillomaviruses (HPV), most 
frequently HPV16, are causally associated with a subset of head and neck squamous 
cell carcinomas (HNSCC). HPV DNA associated tumors appear to be heterogeneous in 
prevalence over time and geographically, in the oncogenic activity (direct and indirect 
viral markers) and clinical behavior. However, it remains unclear which biomarkers can 
reliably determine which HNSCC are truly driven by HPV transformation. 
Aims: In the present thesis, the first aim was to determine the prevalence of the truly 
HPV-associated HNSCC tumors in North-East Italy. The second aim, was to 
investigate the association of HPV DNA positivity with other viral (viral load, oncoE6 
protein, HPV antibodies) and cellular (p16INK4a, pRb) markers. The third aim, was to 
evaluate the prognostic significance of HPV-association tumors for clinical outcome 
(i.e. survival). 
Materials and Methods: Overall, 247 fresh frozen and 53 (21%) formalin-fixed 
paraffin-embedded (FFPE) tumor tissue biopsies and 102 (41%) sera were collected 
from 247 newly detected HNSCC patients from North-East Italy. Clinical parameters 
for each patient were obtained from the clinical database.  
HPV DNA was determined by polymerase chain reaction (PCR) with consensus 
MY09/MY11 primers and Restriction Fragment Length Polymorphism (RFLP) 
analysis and/or BSGP5+/6+-PCR/Multiplex Papillomavirus Genotyping (MPG) 
capable of detecting all known 51 mucosal HPV types.  
The HPV DNA+ tumor tissues were further analyzed for i) viral load by HPV16 qPCR 
and quantitative BSGP5+/6+-PCR/MS; ii) detection of HPV E6*I transcripts by RT-
PCR; iii) expression levels of cellular protein p16INK4a and pRb by IHC; and iv) 
presence of HPVE6 protein for types 16 and 18 by the commercial OncoE6TM Oral 
Test; Antibodies to HPV early and late proteins of the eight most frequent high-risk 
HPV types were determine din all available sera by bead-based multiplex serology. 
Results: Overall, HPV DNA+ was 8.5% (21/247), type 16 was detected in 95% (20 
cases) and type 58 in 5% (1 case). No multiple infections were detected. The HPV 
RNA+ was 6% (14/244). Oropharynx was the site with the highest HPV prevalence by 
DNA (27%) and RNA (20%). In the other anatomic sites,  HPV prevalence was < 8%. 
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Among the HPVDNA+ RNA+ tumors, i) 93% of the HPV16+ tissues (13/14) showed 
high viral load; ii) 60% (6/10) showed both up-regulation of p16INK4a and down-
regulation of pRb; iii) and in 100% (8/8) HPV16 E6 oncoprotein was detected. All sera 
of  7 HPV-driven tumors showed strong positive antibody reactions with HPVE6 and 
E7 proteins, 6 for type 16 and 1 for type 58, type-concordant with the related tumor. 
Another single serum HPV16 DNA+ in the tumor, showed positivity for all early 
HPV16 proteins suggestive of an HPV-driven tumor. Kaplan-Meier analyses for the 
oropharynx showed a trend for better survival in the HPV-associated group than in the 
HPV negative ones. 
Conclusions: A low HPV prevalence was found in HNSCC of the population living in 
the North-East of Italy. Oropharynx was the preferential site for HPV infection while 
the HPV prevalence in the other anatomic sites appeared  negligeable. We observed 
that the HPVDNA+ RNA+ samples showed a good correlation with the other markers 
like high viral load, presence of the E6 oncoprotein, and HPVE6 and E7 seromarkers. 
In contrast to recent reports we did not find a good correlation between HPVDNA+ 
RNA+ and the up-regulation of p16INK4a and down-regulation of pRb. Survival 
analyses showed a better prognosis in the HPV-driven patients with tumors occurring 
in the oropharynx. 
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II. Sommario 
Il papillomavirus umano (HPV), più frequentemente il tipo 16, sono causalmente 
associati agli tumori squamosi di testa collo (HNSCC). Questi tumori sono 
caratterizzati da un'elevata eterogeneità geografica e una migliore risposta alla terapia. 
L'obiettivo di questo studio è di valutare la prevalenza e l'attività biologica di HPV in 
HNSCC nel nord dell'Italia. La genotipizzazione per se non è sufficiente a definire il 
ruolo del virus nella patogenesi HNSCC. E' necessario analizzare e verificare la 
presenza di altri marker diretti come i trascritti virali, la carica virale, oncoE6 proteine e 
anticorpi HPV e dei marker indiretti come l'espressione delle proteine cellulari p16INK4a 
e pRb. I risultati ottenuti sono stati alla fine correlati con la sopravivenza. 
Nel presente studio sono stati arruolati 247 pazienti del Nord-Est dell'Italia. Sono stati 
raccolti biopsie tumorale congelate per tutti i pazienti, e per un sottogruppo dei 
blocchetti di paraffina e del plasma.  
La presenza del DNA virale è stato determinato con i) reazione a catena della 
polimerasi con primer consenso MY09/MY11 e tipizzazione con digestione enzimatica 
e/o ii) BSGP5+/6+ -PCR/Multiplex Papillomavirus Genotype (MPG). I casi HPV DNA 
positivi sono stati ulteriormente analizzati per: i) carica virale (quantitative PCR); ii) 
presenza dei trascritti virali (E6*I method); iii) l'espressione delle proteine cellulari 
p16INK4a e pRb (immunohistochimica, IHC); iv) espressione dell'oncoproteina E6 
(OncoE6TM kit, AVC); v) anticorpi anti HPV (Multiplex HPV serology). 
La prevalenza basata sulla positività del DNA virale era del 9% (21/247). HPV16 è 
stato trovato nel 95% (20/21) dei casi, 1 HPV58 è stato identificato come infezione 
singola. La prevalenza basato sul HPV DNA+RNA+ era del 6% (14/244). L'orofaringe 
era il sito con la più elevata prevalenza di HPV (HPV DNA+ = 27%, HPV DNA+ 
RNA+ = 20%). 86% (12/14) dei campioni aveva un'alta carica virale per il tipo 
analizzato; ii) over espressione p16INK4a nel 90% (9/10), down-regulation pRb nel 55% 
(6/11); iii) la presenza dell'oncoproteina E6 era presente nel 100% (8/8) dei casi testati. 
La presenza di anticorpi anti HPV è stata valutata in 102 plasmi; 8 su 102 erano positivi 
per anticorpi HPV, con elevata correlazione con lo status HPV dei relativi tessuto 
tumorale. Le analisi di Kaplan-Meier per l'orofaringe hanno mostrato un trend di 
migliore sopravvivenza nei pazienti con tumori HPV positivi per DNA e RNA rispetto 
ai pazienti HPV negativi. 
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Bassa prevalenza di HPV nei tumori testa collo nel nord dell'Italia confrontato ad altri 
paesi. L'orofaringe rimane il sito prediletto dell'infezione per l'HPV (27 %). HPV16 era 
il principale tipo trovato (95%). Migliore sopravvivenza dei pazienti con tumori HPV 
positivi.
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1. INTRODUCTION 
1.1 Papillomaviruses 
Papillomaviruses (PV) are small viruses, belonging to the Papillomaviridae family. 
They are widespread in nature, and have been identified in many animal species 1. PV 
are small, non-enveloped DNA (deoxyribonucleic acid) viruses that measure 55 
nanometers (nm) in diameter and comprise an icosahedral capsid (Figure 1) composed 
of 72 pentameric capsomers of the major capsid protein L1, partly associated with the 
minor capsid protein L2. Enclosed within the capsid is the viral genomic DNA which is 
packaged as a minichromosome 2, 3. 
 
 
 
 
Figure 1. Crystallographic structure of HPV capsid (left) and computer-generated model (on the right) 
(From: http://hpvstudy.bol.ucla.edu/hpvbug.htm). 
 
 
 
1.1.1 Papillomavirus taxonomy 
PV phylogenetic classification is based on the nucleotide sequence of the open reading 
frame (ORF) encoding the major structural protein L1, as specified by the International 
Committee on Taxonomy of Viruses (ICTV). PV of different genera share less than 
60% identical L1 nucleotide sequences, PV within a genus share 60 to 70% identity, 
while an identity between 70% and 90% defines a species. PV subtypes show 90 to 
98% and variants more than 98% L1 nucleotide sequence identity. The 
Papillomaviridae family presently consists of 189 PV types spread over 29 genera 
(Figure 2) 4. The Human Papillomavirus (HPV) types are grouped in 5 genera; the 
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alpha (α) genus contains the HPV types most frequently associated with human 
diseases. Based on their tropism, HPV can be separated into cutaneous (skin) and 
mucosal (genital) types 5. Mucosal HPV are mainly sexually transmitted, and the risk of 
infection increases by increasing number of sexual partners 6. Genital HPV infections 
are among the most common sexually transmitted infections 7. Mucosal HPV types are 
also classified on the basis of their oncogenic potential; according to the last evaluation 
by the International Agency for Research on Cancer (IARC) expert group, types 16, 18, 
31, 33, 35, 39, 45, 51, 52, 56, 58, 59 are carcinogenic to humans (Group 1A) and 
designated “high-risk” (hr)-types; the types 26, 53, 66, 67, 68, 70, 73 and 82 are 
defined as probable/possibly carcinogenic (Groups 2A and 2B) 8. Types found in 
benign warts, papillomas or non-malignant lesions include HPV6, 11, 42, 43 and 44 
amongst others, and are defined as “low-risk” (lr)- types 4, 9. 
 
 
 
Figure 2. Phylogenetic tree of 189 PV types. The phylogenetic tree was constructed on the basis of L1 
nucleotide sequences.Numbers at the end of each branch represent HPV types. See the text for detailed 
explanation 4. 
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1.1.2 Human papillomavirus 
1.1.2.1. Genome organization 
The genome organization among mucosal HPV is highly conserved (Figure 3). All 
HPV types contain a single double-stranded circular DNA molecule of around 8,000 
base pairs (bp) replicating as an extrachromosomal plasmid in the nucleus of infected 
keratinocytes. Up to nine ORF are encoded from the same DNA strand and three 
functional areas have been identified: i) the long control region (LCR) or upstream 
regulatory region (URR), that contains numerous regulatory sequence elements, such as 
transcription factor binding sites, viral E2 binding sites, and the origin of viral DNA 
replication with binding sites for the viral E1 protein; ii) the “early” region (E), which 
consists of E1, E2, E4, E5, E6 and E7 ORF, that are involved in viral replication and 
cell transformation; iii) the “late” region which encodes the L1 and L2 structural 
proteins 6, 10, 11. 
 
 
 
Figure 3.Genome organization of mucosal HPV. Early transcripts utilize an early polyadenylation signal 
(poly-A early), (downstream of the E5 ORF). Late transcripts use the late poly-A signal (downstream of 
the L1 ORF). Early proteins E1, E2 and E4 are indicated in green, E5, E6 and E7 viral oncoproteins in 
red and late structural proteins L1 and L2 in 
yellow(http://img.medscape.com/fullsize/migrated/585/223/erm585223.fig2.jpg). 
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1.1.2.2. HPV life cycle 
Papillomaviruses display an unusual life cycle. Unlike most viruses that infect a target 
cell and produce progeny virus from that same cell, in papillomavirus infections the 
initially infected basal cell must undergo mitosis and differentiate to produce new 
virions. Moreover, they do not encode polymerases or other enzymes necessary for 
viral replication, relying on the host cell replication proteins to mediate viral DNA 
synthesis. Two modes of viral DNA replication are recognized, i) the reproductive 
replication, where the virus enters the lower portion of the epidermis and the plasmid is 
maintained by low level replication in synchrony with the cell and the ii) vegetative 
replication, which occurs in the more differentiated epithelia cells in the absence of 
cellular DNA synthesis.   
The mechanisms regulating the switch from plasmid maintenance to vegetative viral 
DNA replication are not known, and may involve changes in cellular and/or viral 
factors occurring in differentiating keratinocytes 12. 
 
Infection by  HPV requires the virus particles to gain access to and enter in the cells of 
the epithelial basal layers (Figure 4). Binding and entry of the virus are mediated 
through the viral coat proteins (L1 and L2) and heparin sulfate proteoglycans (HPSGs) 
and/or α6β4 integrins (way not conserved among the HPV types) 13, 14. Virus uptake 
mostly occurs by clathrin-coated endocytosis (not conserved among all HPV types) 15, 
disassembling of the viral particle in the late endosome/lysosome and transfer of the 
viral DNA to the cell nucleus (facilitated by L2 protein) 16. 
Expression of the early proteins E1 and E2 establishes the viral genome as an episome 
and leads to the expression of the other early proteins (E4, E5, E6 and E7). This phase 
is characterized by a low HPV copy number (approximately 10 to 200 viral copies per 
cell) 17-19.  
 
Upon cellular differentiation, a late viral promoter is activated and drives expression of 
late proteins 20, 21. Expression of L1 and L2 is restricted to cells of the granular layer 
with viral particle assembly taking place in the cornified layer. In this phase the viral 
copy number reaches 1000 viral genomes per cell 2. 
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Figure 4. HPV life-cycle organization and viral protein expression in the cervix. Modified from 22. Blue 
circles, cells expressing early E1 and E2 proteins. With cell proliferation expression of viral oncoproteins 
E5, E6 and E7 increases (red circles) and later also  of E4 protein (green circles). Purple circles represent 
viral L1 and L2 particles required for assembly of infectious viral particles (courtesy of G. Halec). 
 
 
 
1.1.2.3. HPV transcription, transcripts and proteins function 
Regulation of HPV transcription is complex and differs between genotypes. Since 
HPV16 is the most studied and the leading type in HPV-carcinogenesis, its 
transcription mechanisms are presented (Figure 5).  
HPV16 gene expression is regulated by at least two promoters (p97 and p670) 23, 24, 
multiple splice donor and acceptor sites, two polyadenylation signals and further by 
post-transcription mechanisms. All transcripts are polycistronic and synthesized from 
the same DNA strand. Depending on splicing events, up to three different reading 
frames can be employed for translation. The early and late poly-A signals are located at 
nucleotide (nt) 4215 and 7321, respectively. Maturation of viral RNA involves complex 
splicing. The HPV16 transcriptome exhibits several splice donor giving rise to at least 
11 different splice junctions 24-28. The detailed functions of the various spliced 
transcripts are still under investigation. Spliced transcripts can be translated into 
truncated proteins exhibiting important functions for the viral life cycle regulation 29, 30.  
Virus release  
Virus 
assembly
(L1, L2)
Genome 
amplification
(E1, E2, E4, E6, E7)
Genome 
maintenance/ 
Cell proliferation
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In the hr-HPV types, differential expression of E6 and E7 is mediated through a single 
primary transcript that is alternatively spliced in the E6 gene. While the E6 full-length 
(fl) transcript encodes for both E6 and E7 proteins, the spliced transcripts E6*I and 
E6*II encode for E7 only and truncated E6* proteins. Since E7 is the most prominent 
HPV oncoprotein 31, 32 these transcripts have been intensely studied. Increased levels of 
E6/E7 mRNA correlate with cancer progression 33. To better understand the role of 
each E7 coding transcript during cancer progression, quantification of expression 
profiles from E6*I, E6*II, and E6/E7 fl transcripts has been described for pre-
malignant lesions 34-37, cervical cancer 37 and tumor-derived cell lines 34, 38, 39. Spliced 
E6 transcripts might play a role in HPV type carcinogenicity; they have been described 
for the carcinogenic but are not found in non-carcinogenic HPV types 40-42.  
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Figure 5. Transcription map of HPV16R (RNA). ORF of each gene are shown in their proper reading 
frames as colored rectangles (top of the figure). The first number at the upper left end of the rectangles 
corresponds to the nucleotide (nt) position of the ORF start, i.e. the first nt following a stop codon. The 
second number is the nt position of the first ATG, which is also indicated by a dotted line within the 
rectangle. The position of the last nt in the stop codon of each ORF is printed at the lower right corner of 
the rectangles. Located below the genome scale are diagrams of spliced mRNA species and their coding 
potential at the right. Non translated exons are illustrated by black rectangles, while intervening introns 
are indicated by black hairlines. Colored rectangles indicate in-frame sequences that can potentially code 
for proteins. Numbers printed below the lines indicate the 5' and 3' splice junction positions. The 
promoter for the last three transcript i.e. species N-O has not been mapped. Transcripts encoding full-
length E1 and L2 protein are not depicted. Potential truncated gene products of E6 and E1 are indicated 
by asterisks (*). The fusion product of the E1 and E4 protein is indicated as E1^E4. Source 43. (from 
http://pave.niaid.nih.gov/images/transcript/HPV16.png) 
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The E1 protein is required for viral DNA replication, has a helicase activity and binds 
to cellular proteins, including RPA (replication protein A) and DNA polymerase α 
primase 44-47.  
The E2 protein is involved in the viral DNA replication and segregation 48. E2 is a 
DNA-binding protein recognizing a palindromic motif in the non-coding region of the 
viral genome. Via a protein-protein interaction, E2 recruits E1 49. E2 can also be active 
as a transcription factor that regulates the viral early promoter p97 causing auto-
regulation of E2 expression and regulation of the expression of viral oncogenes (E6 and 
E7). At low level, E2 is a transcriptional activator, whereas at high level, E2 represses 
oncogene expression 50.  
 
The E4 ORF is located in the early region and its gene product, E1^E4 is only 
expressed in differentiated, upper epithelial layers and plays a role by binding to 
proteins of the keratin cytoskeleton during virus assembly and virus release 51. It was 
proposed that E1^E4 and E5 (see below) oncoprotein may cooperatively foster viral 
activities since E5- and extracellular signal-regulated kinase (ERK) phosphorylation 
lead to an increase in E1^E4 abundance and stability in infected cells 52. 
 
The E5 protein is one of the three oncoproteins encoded by the virus but its 
biochemical role and precise contribution to human cell transformation are still unclear. 
Is a transmembrane protein that predominantly remains in the endoplasmic reticulum 
(ER). E5 can delay the process of endosomal acidification 53-55, and this leads to an 
increase in EGF (epidermal growth factor)-mediated receptor signaling and the 
maintenance of a replication competent environment in the upper epithelial layer 56, by 
affecting the recycling of growth factor receptor on the cell surface. It has been shown 
that E5 expression is lost during the integration of HPV DNA into the cellular genome 
57
. Since in cervical cancer viral integration occurs during progression, E5 is probably 
not necessary in the late events of HPV-mediated carcinogenesis. 
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E6 and E7 are the major oncoproteins in HPV cell transformation.  
The E6 protein is translated only from RNA containing the fl E6 ORF (Figure 5, 
species A, G, K). HPV16 E6 protein promotes proliferation of infected cells leading to 
their resistance to apoptosis and can induce cell immortalization. E6-driven cell 
immortalization and p53 reduction was demonstrated also for BPV-1 (Bovine 
papillomavirus type 1) and non-carcinogenic HPV6 but with lower efficiency and 
requiring a longer time period in comparison to HPV16 E6 58. Four spliced RNA 
species all using the splice donor at nt 226 and splice acceptors at nt 409 (E6*I), nt 526 
(E6*II), nt 3358 (E6*III) or nt 2709 (E6*iV) 42, 59, 60 can generate two internally 
truncated E6 protein variants (E6*I and *II) or truncated forms fused to short non-E6 
sequences (E6*III or *IV). E6*I transcripts give rise to the truncated E6*I protein and 
the fl E7 protein and have been considered the characteristic of carcinogenic versus 
non-carcinogenic HPV types 42 because E6*I transcripts have been described for 14 
HPV types that occur in cervical cancer as a single infection 24, 61-64 but are not 
generated by mucosal HPV types not associated with cervical cancer 41, 42. E6*I protein 
is translated from 226^409 in HPV16 E6 ORF.  
 
The fundamental action of E6 protein (158 amino acids) of transforming mucosal HPV 
types is its ability degrade p53, through combined activity of an ubiquitin ligase called 
E6-associated protein (E6AP) 65 (Figure 6). This is achieved by formation of E6-E6AP-
p53 protein complex that shortens the p53 half life from 3 hours to 20 minutes and 
more importantly, blocks apoptosis. The ability to bind and degrade p53 was 
demonstrated for majority of the HPV types from the hr-clade (hr HPV16, 18, 31, 33, 
35, 39, 45, 51, 52, 56, 58 and 59 66-69. E6 proteins from lr-HPV types do not bind p53 at 
detectable levels and have no effect on p53 stability in vitro 70. An important feature of 
hr-E6 proteins is the presence of a PDZ-binding motif at the C-terminus, the feature 
that is not shared with lr-HPV types. Multiple PDZ-binding partners have been 
described, all of which are degraded by proteasomes (e.g. Dlg, Scribble, MAGI-1, 2, 3). 
The primary functions of PDZ proteins involve the regulation of cell growth, cell 
polarity, and cell adhesion in response to cell contact. It remains to be determined, 
however, which of E6-PDZ interactions are functionally important in vivo 71.  
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The E6 protein also activates the protein telomerase in differentiated cells resulting in 
an increased life-span of the affected cells. The precise mechanism by which this 
occurs is still unclear. E6 interacts with several other proteins, such as SRC kinases 72 
and the pro-apoptotic BAK 73, thereby enhancing its proliferative and anti-apoptotic 
effect.  
 
E7 protein is translated from both the fl E6/E7 mRNA 24, 74, 75 and from alternatively 
spliced E6*I transcripts (species B, E, I) 42, 59, 60. The E7 protein is considered to be 
transcribed also from E6*II mRNA (species C, F, J) but with a lower efficiency 76. 
E6*II transcripts were found in cell lines 77-79 and precancerous lesion 80, 81 and cervical 
cancer 81 of HPV types 16 and 18 only. Of other HPV types, E6*II of HPV33 have 
been identified but in tonsillar carcinoma 82. 
 
The E7 oncoprotein is the crucial HPV protein in a transgenic mouse model leading to 
cervical cancer development by inducing cell immortalization and transformation 83. 
This nuclear, 100 amino acids protein promotes G1-to-S phase (Figure 6) progression in 
HPV infected cells by targeting numerous cellular substrates for proteasome-mediated 
degradation 84. One of the most eminent functions of E7 is binding to the 
retinoblastoma tumor suppressor family members: p105 (pRb) and its related “pocket 
proteins” p107 and p130 85. The pRb proteins regulate G1-to-S phase transition in the 
cells by binding to the E2F transcription factors 86. Many genes that are involved in 
regulation of the cell cycle progression, mitosis, and apoptosis contain E2F binding 
sites in their promoters 87. The E7 protein binds pRb over its LXCXE motif in the N-
terminal half of the protein which results in E2F release and constitutive expression of 
E2F-responsive genes. Upon E7-pRb binding, pRb protein is targeted for proteasomal 
degradation. Moreover, E2F responsive genes, cyclin A (CyA) and E, (CyE) complex 
with cyclin-dependent kinase 2 (CKD2) and further promote pRb phosphorylation and 
E2F release. 
In addition to pRb binding E7 can also directly interact with E2F factors e.g. E2F1 and 
E2F6 in order to maintain the S phase environment conductive for viral replication 88, 
89
. Another important action of E7 is binding of histone deacetylases (HDACs) and 
therewith facilitating activation of transcription 90-92. Moreover, E7-pRb-HDAC 
interaction is shown to be important for episomal maintenance and maintenance of S 
Introduction 
15 
 
 
phase environment, and therefore is considered a crucial event for successful viral 
replication in suprabasal cells 90, 92. 
Further E7 cellular targets, tumor suppressor proteins p21 and p27, bind to the carboxy-
terminus of hr-E7 oncoproteins which efficiently neutralizes their inhibitory effects on 
CyE- and CyA/CDK2 pRb phosphorylating activities and promotes cell growth and 
proliferation 93, 94. 
The hr-E7 expressing tumor cells disrupt anoikis, a form of programmed cell death, 
through interaction of E7 with the pRb-associated protein p600 that functions as an 
ubiquitin ligase 95. P600 is a cytoplasmic protein, suggesting that E7 can target cellular 
factors in the cytoplasm and in the nucleus. 
The lr-E7 proteins e.g. HPV-6 E7, bind to pRb family members with an affinity that is 
about 10-fold lower than that of hr-E7 proteins 96.  
 
 
L1 is encoded from transcripts initiated at p670, either unspliced or spliced between 
splice donor nt 1302 and splice acceptor nt 5639 (species P) (described in W12 cells 28) 
or nt 3632 (species O). Cell binding studies with non-infectious virus-like particles 
(VLP) that self-assembled from overexpressed L1 or both L1 and L2, showed similarly 
binding characteristics, implying that L1 contains the major determinants for initial 
attachment 97, 98. 
 
L2 protein is produced only from unspliced late transcripts. During late stages of the 
productive infection the major capsid protein, L1, and the minor capsid protein, L2, are 
expressed in differentiated cells near the top of the epithelium. They form the viral 
capsids in the granular layer and virions are believed to be released in a non-cytolytic 
manner. L1 protein has been found only in the upper layers of the epithelium. However, 
L1 and L2 RNA can also be detected in lower epithelial layers 99, 100 indicating that 
their protein expression is also regulated post-transcriptionally. 
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Figure 6. Cell cycle deregulation by HPV infection. The cell cycle is regulated by complexes of cyclins 
and CDKs. Those complexes are in turn regulated by CDK inhibitors, such as p16 and p21. The two cell 
cycle restriction points are depicted as red lines. The HPV16 protein E6 binds cellular p53 leading to its 
degradation. In contrast, cellular pRb is inactivated by HPV16 protein E7. Thus, viral oncoproteins lead 
to entry into S-phase resulting into cell proliferation. In addition, p53-mediated apoptosis is inhibited 
making viral replication possible 101. 
 
 
 
 
 
 
 
1.2 Head and neck carcinomas 
1.2.1 Epidemiology 
Head and neck cancers (HNC) include tumors which arise from oral cavity, 
nasopharynx, oropharynx, larynx and hypopharynx. 
Worldwide, HNC represent the sixth most malignant tumor. Yearly, 500.000 new cases 
are estimated, where approximately 50% of the patients die due to the disease 102.  
The incidence of HNC varies considerably throughout the world as illustrated in Figure 
7 103 with incidence peaks in Southeast Asia, parts of Central and south-western Europe 
(Spain, France) and Brazil, and low incidence figures in Japan, China and West Africa.  
The observed incidence variation of HNSCC appears mainly to be due to a variation of 
carcinogen exposure intensity (tobacco smoking, alcohol, HPV infection, betel quid, 
oral hygiene).  
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In the developed world, high incidence figures of HNC in certain regions including 
Western Scotland and Eastern Europe/Russia are attributed to heavy tobacco and 
alcohol consumption 104, while consumption of Betel nut/Betel quit (beside tobacco and 
alcohol) is an important contributor to the high incidence figures in the developing 
world, particularly South East Asia (up to 75% of the population). 
In addition to geographic variation, the incidence of HNC has been characterized by 
significant temporal variation over the last 50 years. Overall incidence rates show a 
declining trend in both sexes in India, Hong Kong, Brazil and USA whites 105, while an 
increasing trend is observed in most other populations, particularly in Central and 
Eastern Europe, Scandinavia, Canada, Japan and Australia. 
 
 
 
 
Figure 7. Geographic distribution of head and neck cancer.Estimated age-standardized incidence rates 
per 100,000, both sexes, all ages, Globocan 2008. 
 
 
 
 
In Italy, head and neck tumors represent about 5% of all malignant tumors, and rank5th 
infrequency. Each year about 12,000 new cases are diagnosed. The incidence rate 
(standardized to the European population) is 16 cases per 100,000 Italians per year, 
while in Europe (EU countries) it is equal to 18 per 100,000. The incidence rates are 
higher in the northern regions of Italy than the central and southern areas and islands. 
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In Italy, the risk of developing HNC is 7 times higher in males than in females; the 
incidence is particularly high in Veneto with a rate of 48 per 100,000 in men and 8 per 
100,000 in women (ratio 6:1). The most affected age group is between 50 to 70 years 
old 106. 
 
 
 
1.2.1 HPV related to head and neck carcinomas 
1.2.1.1 Incidence and risk factors 
A worldwide systematic review from Kreimer and collaborators, reported an overall 
HNSCC HPV prevalence of 25.9%. HPV prevalence was significantly higher in 
oropharyngeal squamous cell carcinoma (OSCC) (35.6%) than oral SCC (23.5%) or 
laryngeal SCC (24%) 107. However, a wide variation of HPV-positive OPSCC is 
reported in the literature, varying from 4.4% up to 93% 108, 109.  
While HN-tumors showed a decline/unchanged incidence in the last decades, an 
increase of the HPV-associated head and neck cancer, particularly for the oropharynx 
was observed 110-112.  
In the US population the yearly increase of the new-OSCC was estimated to be 5% 113. 
In a recent publication from Denmark, a 6-fold increase of incidence rates for tonsillar 
carcinoma were reported in male patients for the time between 1978-2007 114. Norway 
between 1991 and 2005 reported increasing rates of 5% for males and 4.2% for females 
115
. Spain, reported an increase of 4.3% from 2000 to 2009 112. 
In the healthy population, the oral HPV prevalence was estimated to 4.5% overall, 
where HPV type 16 had the highest prevalence (1.3%) among all the other hr-HPV type 
found 116. 
 
This incidence increase is probably in line with the change of sexual practices. Even 
though data are still lacking, Herrero et al.117 showed that oral sex was reported 3 times 
more often by the HPV-positive group than the HPV negative group in the 
oropharyngeal cancer. Other risk factors are the number of sexual partners 118, an early 
beginning of sexual life and homosexual contacts 119. Controversial are the data 
regarding the association of HPV and smoking in relation to OPSCC carcinogenesis. 
HPV is an established risk factor for OPSCC in non-smokers but there are a significant 
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number of HPV positive patients that are ex/light-smokers, and smoking might act as a 
promoter 120. 
1.2.1.2 Molecular markers in the HPV-associated HNSCC 
HPV DNA: most of the techniques in use for HPV DNA detection, are PCR-based 
techniques, most of them use general (or consensus) primers targeting highly conserved 
regions of L1 121-127. However, depending on the material biopsy (fresh frozen tissues 
and FFPE) a different sensitivity is achieved. For e.g. the MY09/11-RFLP method, 
which gives a product of 450 bp is approximately 10-fold less sensitive than the BS-
L1-MPG51) 126, 127 or 87.9% sensitivity compared to the HPV type-specific PCR 128. 
HPV RNA: only a subset of HPV DNA positive tumors display carcinogenic activity in 
the tumor tissue, defined as HPV-driven. Thus, HPV DNA alone is not sufficient to 
determine the causal involvement of any HPV found in the tumoral tissue. The 
oncogenic potential of HPV types is related to their ability to express the viral E6 and 
E7 oncoproteins that are translated from bicistronic or polycistronic mRNAs in infected 
cells 42, 60, 76. Splicing of mRNA transcribed from the E6 open reading frame (ORF) is 
considered a biological feature of hr-HPV, but not lr-HPV 41, 42. Splice sites within the 
E6 ORF, giving rise to the most abundant E6*I transcript, have been described for all 
12 hr-HPV, and for probable hr-HPV types 66 and 68 24, 61, 63, 64, 82, 129. Continuous 
E6/E7 expression is required for the maintenance of the transformed phenotype of HPV 
positive tumoral cells. Recently, an ultra-short amplicon, E6*I mRNA RT-PCR assay 
has been described for HPV16 130, 131. Advantages of such an assay are applicability to 
FFPE material and absolute RNA specificity by using a splice-site as identification 
target. 
Cellular markers HPV tumor related: as described (see section 1.1.2.3), the E6 and E7 
oncoproteins bind to, and regulate steady state levels of cell cycle proteins p53 and 
pRb. As a consequence, increased p16INK4a expression occurs as an indirect 
consequence of E7-induced pRb inactivation (down-regulated) 132-135. Therefore, 
p16INK4a and pRb are considered surrogate markers of HPV involvement. Their 
expression in the cells can be easily analyzed by IHC methods. Analyses require FFPE 
materials. 
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Other potential markers are HPV-induced antibodies against the HPV proteins. Initial 
HPV infection induces both systemic and local humoral immune responses 136, 137. The 
serum antibodies (Abs) to L1 capsid protein are induced in 50–70% of infected patients 
months after HPV infection and are detectable for years after clearance of the infection; 
they represent past and/or present HPV exposure 138, 139. Antibodies (Abs) to HPV16 E6 
and E7, were reported as the best markers in invasive cancers 117, 140-142. The frequency 
of virus-like capsid particle (VLP), E6, and E7 seropositivity is directly associated with 
the presence of HPV DNA in the tumour 107, 143. Seropositivity for HPV16 E6 or E7 is 
strongly associated with the odds of OPC (64% of cases; OR: 58) 144, and predicts an 
improved prognosis 145. Humoral immunity to other HPV early gene (E1, E2 and E4) 
products has not been well evaluated, and the relationship of early gene Abs to the 
pathogenesis and prognosis of OPC and other HPV-related. 
 
 
1.2.3 Clinical characteristics and diagnostic implication 
HPV-induced HNSCC have a peculiar clinical presentation with regard to both tumor 
and neck stage and characteristics.  
Patients with HPV positive HNSCC tend to be younger by approximately 5 years, on 
average, when compared with HPV-negative HNSCC patients 146-148. With regard to 
sex, men appear to be at equal risk to women. It is clear that the majority of HPV 
positive tumors arise largely from the lingual and palatine tonsils in the oropharynx, 
compared with other anatomic sites of the head and neck 105, 149. Compared to HPV-
unrelated tumors, HPV-induced carcinomas are generally diagnosed in earlier T-
category with a trend for a more advanced N-category 150. Extreme clinical 
manifestation of HPV-related HNSCC is a neck metastasis from occult primary tumor 
151, 152
. Histopathologically, HPV positive tumors tend to have a poorly differentiated 
and frequently basaloid histology 153.  
It has been reported a better response of HPV-associated tumors, particularly to 
radiotherapy (RT). The possible mechanisms underlying immune-enhancing like an 
increased uptake of antigen-containing dead cells killed by radiation, normalization of 
tumor vasculature that enhances immune system cells to the tumor bed, production of 
induces pro-inflammatory cytokines (like TNFα), also, the tumor microenvironment, 
may contribute to the greater radiosensitivity 154. 
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1.3 Aim of this thesis 
Only a subgroup of the head and neck squamous cell carcinomas is truly caused by 
HPV transformation. It is now well established that HPV DNA alone is not sufficient to 
determine HPV-causality in HPV-infected cancer tissues. Thus, detection of 
transcriptional activity is a primary and necessary condition to define HPV 
carcinogenicity, which also has a relevant impact on detecting truly HPV-associated (or 
driven) tumors. The first aim of this thesis was to determine the prevalence of the HPV-
driven tumors in patients affected by HNSCC living in North-East of Italy. 
 
The RNA material to detect the presence of viral HPV transcripts is not always 
available (i.e FFPE blocks), therefore the expression of cellular markers should be 
analyzed for HPV involvement. The second aim, was to analyze additional viral load, 
oncoE6 protein, HPV antibodies) and cellular (p16INK4a, pRb) markers, and investigate 
their association with HPV DNA positivity.  
 
Several studies have reported a better survival of HPV positive HNSCC patients, 
particularly when the anatomic site involved was the oropharynx. So, the third aim of 
the project was to evaluate the prognostic significance of HPV-association with clinical 
outcome (i.e. survival). 
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2.MATERIALS 
2.1 Consumables 
Adhesion glass slides (Super Frost® Plus)   Menzel-Gläser, Braunschweig   
   (Germany) 
Cover glasses (24x50 mm)   Knittel, Bielefeld (Germany) 
Centrifugetubes (15 ml)   Thermo Scientific, Wilmington   
   (USA) 
Centrifugetubes (CELLSTAR® Tubes; 50 ml) Greiner Bio-One, Frickenhausen     
Filter tips   Starlab GmbH, Ahrensburg    
   (Germany) 
Filter washplates (MultiScreen® HTS; 96-well) Millipore, Bedford (USA) 
Glass slideboxes   Neolab, Heidelberg (Germany) 
Glass cuvettes (forstaining)   Neolab, Heidelberg (Germany) 
Glass shuttles (for staining)   Neolab, Heidelberg (Germany) 
Microtome blades (Leica 819)   Leica Microsystems, Wetzlar   
   (Germany) 
Oligonucleotide beads (SeroMapTM beads)  Luminex Corp., Austin (USA) 
Output plates (MagNA Pure 96 Output Plate)  Roche Applied Science, Mannheim 
(Germany) 
PCR plates (μultra Amp Skirted 96 PCR Plates; Sorenson, Bioscience Inc., Utah  (USA) 
nuclease-free; 96-well)  
PCR plates (LightCycler®480 Multiwell Plate96) Roche Applied Science, Mannheim 
(Germany) 
Reaction tubes (Safe-Lock Reaction Tubes1.5 ml;  Eppendorf, Hamburg (Germany) 
nuclease-free)  
Reaction tubes (Quali-Low Retention;   Kisker Biotech, Steinfurt    
nuclease- &pyrogen-free)    (Germany) 
Sealing foils (MagNA Pure 96 Sealing Foil) Roche Applied Science, Mannheim 
(Germany) 
Sealing foils (LightCylcer® 480 Sealing Foil) Roche Applied Science, Mannheim 
(Germany) 
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Sealing foils (for PCR plates)   Roche Applied Science, Mannheim 
(Germany) 
Thermomix (Vortemp 56)    Labnet, Laborsysteme, 
RledImmInkrels     (Austria)  
 
2.2 Chemicals 
Acetic acid (glacial, 100%)    Merck, Darmstadt (Germany) 
Acetone absolute     Sigma-Aldrich, Steinheim  
       (Germany) 
β-Mercaptoethanol     Sigma-Aldrich, Steinheim  
       (Germany) 
Casein (from bovine milk)    Sigma-Aldrich, Steinheim  
       (Germany) 
DAB Substrate Kit for Peroxidase    Vector Laboratories Inc.,  
  Burlingame (USA) 
DAKO-buffer      DakoDenmar 
Distilled water (nuclease-free)   GIBCO Life Technologies, Paisley 
       (Scotland) 
dNTPs (each 25 mM)     Carl Roth, Karlsruhe (Germany) 
EDTA-Disodium (RNAse-free)   Applicem, Darmstadt (Germany) 
EDTA (0.5 M)     Applichem, Darmstadt (Germany) 
Eosin G (C.I. 45380, formicroscopy)  Carl Roth, Karlsruhe (Germany) 
Ethanol absolute     Sigma-Aldrich, Steinheim  
       (Germany) 
Eukitt       O. Kindler GmbH, Freiburg  
       (Germany) 
Mounting medium (Eukitt®)    Kindler, Freiburg (Germany) 
Haemalaun (Mayer´s Haemalaun   Applichem, Darmstadt (Germany) 
Solution, ready-to-use solution)   
Magnesium chloride     Merck, Darmstadt (Germany) 
RNAse Away Spray     Molecular Bioproducts, San Diego 
       (USA) 
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TE buffer, RNAse-free, 1x    Acros Organic, Geel (Belgium) 
Tetramethylammoniumchloride (TMAC)  Aigma-Aldrich, Steinheim  
       (Germany) 
Tris-HCl, 1 M, pH 8.0, RNase-free   Jena Bioscience, Jena (Germany) 
Tween® 20      Serva Electrophoresis, Heidelberg 
       (Germany) 
xMAPTM Sheath Fluid    Luminex Corp., Austin (USA) 
Xylene      Sigma-Aldrich, Steinheim  
       (Germany) 
Phenol/Chloroform Carl     Roth, Karlsruhe 
Sodiumacetate (NaAc)     J.T. Baker, Deventer (The  
       Netherlands) 
N,N,N’,N’-Tetramethylethylendiamin (TEMED)  Merck, Darmstadt 
 
 
 
2.3 Prepared Buffers 
2.3.1 DNA Extraction Buffer 
DDL Buffer      45 mMTris-HCl 
0.9 mM Na2EDTA 
0.45% Tween® 20 
pH 8.0 
 
 
2.3.2 Solution and Buffers for Luminex Bead Detection 
Detection solution Luminex DNA/RNA  2 M TMAC 
75 mMTris-HCl, pH 8.0 
6 mM EDTA, pH 8.0 
1.5% Sarcosyl 
1 mg/ml Casein 
 
Hybridization solution Luminex   0.15 mM TMAC 
DNA/RNA      75 mM Tris-HCl, pH 8.0 
6 mM EDTA, pH 8.0 
1.5% Sarcosyl 
Hybridization wash buffer Luminex   0.02% Tween® 20 
1 x PBS, pH 7.4 
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PBS (Phosphate-buffered saline), 1x,   124 mMNaCl 
pH 7.4       22 mM Na2HPO4 
10 mM KH2PO4 
 
 
 
2.3.3 Enzymes 
Proteinase K (recombinant, PCR grade)  Roche Diagnostics, Mannheim 
       (Germany) 
DNAseI (RNAse-free)    Qiagen, Hilden (Germany) 
Rsa I        Roche Diagnostics, Mannheim 
       (Germany) 
Hae       Roche Diagnostics, Mannheim 
       (Germany) 
Dde III       Roche Diagnostics, Mannheim 
       (Germany) 
 
 
2.3.4 Commercial Kits 
LightCycler® 480 Probes Master    Roche Applied Science, Mannheim 
       (Germany) 
LightCycler® 480 RNA Master  Roche Applied Science, Mannheim 
Hydrolysis Probes (Germany) 
MagNA Pure 96 DNA and Viral NA Roche Applied Science, Mannheim 
Large Volume Kit  (Germany) 
PureLinkTM FFPE Total RNA   Invitrogen, Karlsruhe (Germany) 
Isolation Kit, Qiagen Multiplex PCR Kit   Qiagen, Hilden (Germany) 
 
 
 
2.4 Oligonucleotides and Oligonucleotide probes 
PCR primers for BSGP5+/6+-PCR/Multiplex HPV Genotyping126, 127as well as the 
probes for subsequent hybridization and PCR primers for the viral load determination 
(qPCR) were established by Dr.Markus Schmitt (DKFZ). All primers were ordered in 
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HPLC purification quality and all probes had a 5´-amino C12-spacer modification. 
Primers and probes were obtained from MWG Biotech AG (Ebersberg, Germany).PCR 
primers and probes for the HPV E6*I mRNA analysis (ultrashort RT-PCR)64, 155, 
156were obtained from Sigma-Aldrich (Hamburg, Germany). Backward primers were 
biotinylated to allow subsequent Luminex-based detection of hybridized amplimeres. 
PCR primers and probes for HPV16 RNA pattern assay were obtained by Roche 
Molecular Diagnostics (Pleasanton, USA) and Sigma-Aldrich (St. Louis, USA) in 
HPLC purification quality. 
To protect intellectual property, oligonucleotide primers and probe sequences are not 
shown.
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2.5 Laboratory devices 
Centrifuge (Haraeus Fresco 17)   Thermo Scientific, Wilmington 
       (USA) 
Cooling plate (EG 1150 C)     Leica Microsystems, Wetzlar 
       (Germany) 
Horizontal shaker (Unimay 1010)    Heidolph Instruments, Schwabach 
       (Germany) 
Light cycler (cobas z 480)    Roche Applied Science, Mannheim 
       (Germany) 
Light microscope     Leica Microsystems, Wetzlar 
       (Germany) 
Luminexanalyzer (Luminex® 200TM)   Luminex Corp., Austin (Germany) 
Luminexsheathfluiddelivery system)   Luminex Corp., Austin (Germany) 
(Luminex® SDTM 
MagNA Pure 96 System   Roche Applied Science, Mannheim 
(Germany) 
Microtome (RM 2245)     Leica Microsystems, Wetzlar 
       (Germany) 
Mini centrifuge (UltraCruzTM)   Santa Cruz Biotechnology, Dallas 
       (USA) 
Mini platespinner (MPS 1000) LabnetLaborsysteme, 
RiedimInnkreis (Austria) 
Multichannel pipette, 8-channel, 20-200 μL  Brand, Roskilde (Denmark) 
Pasteur Pipettes     Sigma-Aldrich, Steinheim  
       (Germany) 
PCR thermocycler (Mastercycler®)    Eppendorf, Hamburg (Germany) 
PCR workstation (captair® bio)   Erlab, Köln (Germany) 
Pipettes (PipetmanNeo®)    Gilson-Ambimed, Düsseldorf 
       (Germany) 
Pipetting robot (Qiagility)    Qiagen, Hilden (Germany) 
Thermomixer (Vortemp 56) Labnet Laborsysteme, Ried im 
Innkreis (Austria) 
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Vaccumwashstation     Millipore, Bedford (USA) 
Vortexmixer (Vortex-Genie 2)    ScientificIndustries, Bohemia 
       (USA) 
 
2.6 Software 
Luminex 100 IS 2.3 SP1 Software    LuminexCorp., Austin (TX, USA)  
Microsoft Office     Microsoft Corp., Unterschleißheim 
Microsoft Windows XP     Microsoft Corp., Unterschleißheim 
GraphPadPrism® 6    GraphPad Software, Inc. La Jolla, 
(CA, USA) 
SAS 9.3    SAS Institute Inc., Cary (NC, USA) 
LightCycler Probe Design software 2.0   Roche MolecularDiagnostics (CA,    
    USA) 
 
 
2.8 Study participants 
A total of 247 samples collected from patients from Northern-Italy were recruited in the 
present study. Any patient who visited the ENT (Ear Nose and Throat) Unit from 2003-
2012, and was diagnosed for the first time with a head and neck squamous cell 
carcinoma (HNSCC) was enrolled. In the first 3 years (2003-2006) of the project only 1 
ENT was involved (Treviso Regional Hospital Treviso), subsequently other 2 ENT 
Units joined (Hospital of Mirano, Mirano and Hospital of Cattinara,Trieste). 
Prior to joining the project the patient was informed from the clinician about the study 
and signed a written informed consent adapted from D’Souza 2007 144. From each 
patient a fresh tumor biopsy was collected from the ENT surgeon, before the start of 
any treatment, A part of the tumor biopsy to, after embedded in formalin and was used 
for histological evaluation  from the the Pathology Department of each ENT units 
participating the study , while the other part of the biopsy was used as a frozen biopsy 
for molecular analyses. For a subgroup of the patients serum samples were collected 
within the same day of tumor biopsy collection. 
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Four anatomical sites from head and neck region were included, the oral cavity, 
oropharynx, larynx and hypopharynx. Anamnesis data regarding age, gender, and 
tobacco and alcohol consumption, treatment and follow-up were collected for each of 
the patients. 
 
2.9 Ethical clearance 
The study, for all the 3 ENT units, was approved by the regional ethic committee for 
clinical experimentation (CEP) of Treviso with the study codes 345/AULSS9 and 
421/AULSS9. 
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3. METHODS 
3.1 Sectioning of tissues 
3.1.1 Cryosectioning of fresh frozen tissues 
Sections were cut from frozen biopsies using a cryostat (Leica CM1815) as described 
157
. For each biopsy the first 16µm section was discarded in order to remove surface 
contaminations and obtain a flat surface. A 4µm section was taken for hematoxylin-
eosin (H&E1) staining, followed by 16µm thick tissue sections (yielding 5 mg of tissue) 
for DNA analyses and a second section for H&E (H&E2). The sections were collected 
in DNaseRNase free 1.5 ml Eppendorf homogenized with a single-used pestle and 
stored at -80°C until further use. The above sectioning described the sectioning 
protocol performed at the DKFZ, in Heidelberg, while the sectioning protocol used in 
Padua, was different regarding the model of the cryostat (Leica CM 1915) and the 
homogenization with the single-used pestle which was not performed. The HPV DNA 
positive tumor tissues were re-sectioned for RNA extraction. 
To avoid cross-contamination different precautions were taken. Before starting, and 
after each tissue the cryostat was thoroughly cleaned with acetone and absolute ethanol. 
For each biopsy a new disposable microtome blade was used. To confirm cross-
contamination free sectioning mouse brain tissue was included after each 5th human 
tissue.  
 
3.1.2 Sectioning of FFPE tissues 
All FFPE tissue blocks were sectioned using the Leica microtome as described 135.The 
sectioning procedure is described in section 3.1.1. 
Prior to sectioning tissue blocks were cooled down by placing them in a-20°C 
refrigerator for approximately 60 minutes. Tissue sections for DNA and RNA analyses 
were placed into DNaseRNase free 1.5ml Eppendorf tubes. For H&E staining and 
immunohistochemistry (IHC) sections heated to 36°C in a water bath were placed on 
microscope slides and dried in a 37°C oven for 24 hours prior to staining. 
Contamination controls (rat liver) were constantly included after each 5th tissue block. 
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3.2 H&E staining 
To confirm the histology and to determine the tumor content of the fresh frozen and 
FFPE tissue blocks biopsies, 4µm sections were stained with H&E. Hematoxylin stains 
the cell nuclei in blue, while the eosin stains the cytoplasm in red. After the sections 
were mounted on slides, they were dried for at least 24 hours at room temperature and 
then placed for 10 minutes in the hematoxylin staining solution. Thereafter, the sections 
were rinsed with tap water, and bathed for 10 minutes in 1% eosin solution,  briefly 
washed with ddH2O,dehydrated in an ascending ethanol series (70%, 96% and 100%, x 
min each step), bathed in xylene and finally covered with a coverslip embedded with 
Eukitt. 
The slides were evaluated by D.H. and L.B. Samples with no tumor cells present in the 
H&E stained slides, defined as “absent neoplastic cells”, were excluded from the study. 
 
3.3 DNA extraction  
3.3.1 Phenol-Chloroform (PC) DNA extraction of frozen tissue sections 
The method is based on liquid-liquid extraction, which separates mixtures of molecules 
based on their differential solubility 158. The PC extraction method was performed only 
for the samples sectioned in Padua, which protocol did not include the pestle 
homogenization (see section 3.1.1). 
The sections were digested overnight at 37°C after adding 500 µl of TE buffer,10 µl 
Proteinase K (10 mg/ml), 25 µl SDS 25%. Following, 500 µl of phenol-chloroform 
(phenol-chloroform mixture consisting of 100 ml of phenol (Sigma), 10 ml 50 mM 
TRIS HCl, pH 9.0, 100 ml chloroform) was added to the lysed samples. Subsequent 
centrifugation of the mixture yields 2 phases: the lower organic phase (containing 
proteins) and the upper aqueous phase (containing the nucleic acids). The upper phase 
was transferred to another DNase RNase free Eppendorf tube and 1 volume of 
Chloroform (Sigma) was added, in order to remove residual phenol. DNA was 
precipitated by adding 50 µl of Sodium Acetate (3M p.H. 5.2) and 100 µl of 99% cold 
ethanol, washed once with 70% ethanol and resolved in ddH2O. The DNA samples 
were stored at -20°C. 
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3.3.2 DNA extraction from fresh frozen tissues with MagNAPure 96 kit 
DNA extraction was performed according to the manufacturer´s recommendations for 
the MagNA Pure 96 DNA and viral NA Large Volume Kit 159. The technique’s principle 
is based on the MagNA Pure Magnetic Glass Particle (MGP) Technology. This DNA 
extraction method was applied only to the fresh tumor biopsies sectioned at the DKFZ.  
After the sections were lysed, the DNA were released and the nucleases were 
denatured. The binding between NA and silica surface of the MGP is favored by the 
chaotropic salt conditions and the high ionic strength of the lysis/binding buffer 
(guanidine thiocyanate). MGP with bound DNA were magnetically separated from the 
residual lysed samples. Unbound substances were removed by several washing steps. 
Purified DNA was resolved in 200 µl of elution buffer provided in the kit and stored at 
-20°C. 
 
3.3.3 DNA extraction from FFPE tissue sections 
DNA extracted from FFPE samples is usually of lower molecular weight than DNA 
from fresh frozen samples. The degree of fragmentation depends on the type and age of 
the FFPE sample and the conditions used for fixation. Isolation of DNA was performed 
according to the DDL protocol (Delft Diagnostic Laboratory) with some modifications 
160
. Tissue sections were treated with Proteinase K solution consisting of 1mg/ml 
Proteinase K dissolved in an in house-prepared DNA extraction buffer (DDL buffer) 
prepared as described in section 2.3.1. 
For preparation of Proteinase K solution 25mg of lyophilized Proteinase K was 
dissolved in 25ml DDL buffer, resulting in a final concentration of 1 mg/ml Proteinase 
K.  
Approximately, 300 μl of Proteinase K solution was added to the samples followed by 
vortexing, centrifugation and overnight incubation in a thermomix at 56°C (50 rpm, 
round per minute). Proteinase K was inactivated at 72° for 10 min and samples were 
spun (8000 x g, 2 min) in order to separate the light liquid paraffin from the dense 
aqueous phase.  
Paraffin-free lysates were transferred into new 1.5ml DNaseRNase free Eppendorf 
tubes. When no distinct paraffin layer was formed in the lysates, samples were reheated 
(72°C, 2 min) centrifuged and transferred for a second time. At least one buffer control, 
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comprising Proteinase K solution without tissue, was included per run (24 tissue 
samples). The obtained lysates were stored at -20°C until use. 
 
3.4 RNA extraction methods 
3.4.1 RNA extraction from fresh frozen tissues 
The RNA extraction from homogenate sections was performed using the RNeasy Mini 
Kit and QIAshredder (Qiagen) following the manufacturer’s instructions.  
Briefly, 350 µl of lysis buffer (Buffer RTL) were added to the homogenized sections. 
The lysate was transferred to the Qiashredder column (used for further tissue 
homogenization) and spun. The lysate was transferred to a new reaction tube, mixed 
with 350 µl of 70% ethanol, and transferred to the QIAamp spin column where it bound 
to the silica membrane, followed by a first washing step. To ensure only RNA 
amplification 10 µl of DNaseI stock solution and 70 µl buffer RDD were gently mixed 
and applied to the QIAamp column and incubated for 15min at RT. Afterwards, 350µl 
of a washing buffer (RW1 buffer) was added, centrifuged at 8000xg, 15s, and the flow-
through was discarded. The washing step was repeated twice. To remove ethanol 
residuals, the QIAamp columns were centrifuged with open lids at maximum speed for 
1 minute. The RNA was eluted in 50µl RNase-free water and stored at -80°C. 
 
3.4.2 RNA extraction from FFPE tissue sections 
Total RNA was prepared from FFPE tissue sections using the PureLink FFPE Total 
RNA Isolation Kit (Invitrogen, Carlsbad, California, USA) according to the 
manufacturer’s instructions slightly modified by adding DNase I (RNase-Free DNase 
Set, Qiagen, Hilden, Germany) treatment on the RNA purifying columns during sample 
processing. 
Briefly, 300 μl of Melting Buffer were added to each Eppendorf tube with tissue 
sections followed by incubation at 72°C to melt the paraffin. After spinning the 
samples to collect any condensation, 20 μl of Proteinase K (20 mg/ml) was added to 
each sample followed by incubation at 60°C for 3 – 5 hours until complete lysis. The 
lysate was transferred into new DNaseRNase free 1.5 ml eppendorf tube (see section 
3.3.3). Selective RNA binding to the silica membrane was ensured by prior addition of 
Binding Buffer to the sample. Unspecific binding to the spin column membrane was 
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removed by three washing steps with Wash Buffer. DNase treatment (for conditions see 
section 3.4.1) was carried out between 2nd and 3rd washing step. Extracted RNA was 
eluted in 50μl of RNase-free water and stored at - 80°C until further use. 
 
 
3.5 HPV DNA analyses  
3.5.1 HPV amplification with MY09/11 PCR followed by RFLP 
The MY09/11-Restriction Fragment Length Polymorphism (RFLP) assay can identify 
49 different mucosal HPV types 161, 162. 
The MY09/11 primers amplifyL1 region sequences generating an amplicon of 450 base 
pair (bp) long. In a separate PCR, the sample DNA validity was tested by amplifying 
celluarsequences(β-globin gene) which gives an amplified product of 268 bp. Sample 
positivity/negativity, for both PCRs, were defined by visual inspection after PCR 
product separation in a 2% agarose gel. HPV-positive MY09/11 PCR products were 
digested with type II restrictions endonucleases. These enzymes hydrolyze 
phosphodiester bonds of double-stranded DNA in a sequence-dependent manner 
leaving blunt, or 5´-or 3´-protruding ends.Ten µl of the amplified product was digested 
with 3 different restriction enzymes: RsaI (extracted from the microorganism 
Rhodopseudomonassphaeroides), Hae III (extracted from Haemophilusaegyptius) and 
DdeI (extracted from Desulfovibriodesulfuricans) (Roche Diagnostics, Germany). Each 
of the enzymes gives a specific DNA fragment pattern that after gel electrophoresisof 
the digested PCR products allows identification of the HPV type/s162. 
 
3.5.2 BSGP5+/6+-PCR/Multiplex HPV Genotyping 
The BSGP5+/6+-PCR/MPG51 assay comprises the BSGP5+/6+-PCR, which 
homogenously amplifies ~150 bp from the L1 region all known 51 mucosal HPV types, 
sequences of the β-globin gene and internal standards127 and the MPG hybridization 
assay with bead-based LuminexxMAP suspension array technology, able to 
simultaneously detect the 51 HPV types and the β-globin gene 126, 163, 164. Briefly, 
amplification was performed using the Multiplex PCR Kit (Qiagen, Hilden, Germany) 
using 0.2 – 0.5µM of each BSGP5+ and 5´-biotinylated BSGP6+ primers and 0.15µM 
of each β-globin primer MS3 and 5´-biotinylated MS10. Following PCR amplification, 
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10µl of each reaction mixture was hybridized to bead coupled probes as described 127. 
Bound biotinylatedamplimers were quantified with the Luminex 100 analyzer. For each 
PCR product the median reporter fluorescence intensity (MFI) of at least 100 beads was 
computed for each bead set. As described earlier 165, acut-off value of 5 net MFI to 
define HPV positivity was applied. 
 
 
3.6 HPV viral load analysis 
3.6.1 HPV viral load from BSGP5+/6+ - PCR/MPG analyses 
Quantification of HPV signals was implemented with the MFI values obtained by the 
BSGP5+/6+ - PCR/MPG51assay. In detail, for each positive reaction, the relative HPV 
MFI signal (%) was computed by dividing the measured HPV MFI value with the 
maximum value detected of this HPV type using saturating amounts of PCR product 
obtained from direct PCR of plasmid-containing bacterial colonies. Finally, the relative 
MFI (%) was divided by the measured β-globin MFI value to form a non-descriptive 
viral load value (%HPV MFI/β-globin MFI). High viral load was assessed for all HPV 
types by a HPV type-independent high viral load cut off (0.0007 units) correlating to 
0.5 HPV copies per cell, as recently described 163, 166. 
 
3.6.2 HPV16 ultra-short quantitative PCR (viral load determination) 
Viral load of HPV16 DNA positive samples was determined by TaqMAN probes-based 
quantitative real-time PCR (qPCR) assay (Schmitt et al. manuscript in preparation).In 
intact probes the reporter fluorescence signal is suppressed, due to closeness of the 
reporter to the quencher (Figure 8). During PCR the hybridized probe is hydrolyzed by 
the 5´nuclease activity of the polymerase resulting in separation of quencher and 
reporter dye. Hereby the quencher cannot repress the reporter activity anymore, leading 
to fluorescence emission after excitation with a particular wavelength. Generated 
signals are expressed as crossing point (Cp) values indicating the particular cycle with 
fluorescence above cut off. 
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Figure 8. Schematic principle of quantitative PCR using TaqMan probes and the sigmoidal profile of 
fluorescence accumulation across cycles during amplification (courtesy of D. Höfler). 
 
 
The HPV16 qPCR assay used to determine the viral load, involves a multiplex 
detection of a 104 bpamplimer of the HPV16E6 and a 110 bpamplimer of the human β-
globin sequence. 
The PCR reactionswere performed in a 10 μl volume containing 5 μl of 2x Light Cycler 
Probes master mix (Roche Diagnostics, Manheim, Germany), 0.5 μM of each 
respective primer, 0.2 μM of each probe, and 1μl DNA template. The amplification 
conditions were 10 min at 95°, followed by 45 cycles of 95°C for 10 s, 60°C for 30 sec 
and 70°C for 1 sec. 
 
Forward primer Probe
QuencherFlourophore
Backward primer
5
3
Amplification assay
5
3
Probe displacement
and cleavage
Polymerisation
5
3
Flourescence
Amplification curve
Cp:19.5 23 39.633.526.3 29.6 35.5
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Standard curves for HPV16E6 were obtained by amplification of a dilution series of 
1x106to 1 copy of a plasmid clone containing the HPV16 full-length genome in 50ng/µl 
of human placenta DNA. 
The standard curve for β-globin was obtained by a dilution series, ranging from 100 to 
0.01 ng of human placenta DNA. 
Absolute quantification of genome copy numbers was achieved by linear regression 
analysis comparing the Cp values of the unknown sample against the standard curve 
with known copy numbers. The predefined cut-off for high viral load was 0.5 HPV 
genome copies/cell, and samples with less than 100 cells (cut off) were considered as 
invalid samples and were not evaluated for statistical analyses. The detection limit of 
the assay is less than 100 HPV16 genome copies. 
 
 
3.7 HPV RNA analysis  
3.7.1 E6*I mRNA RT-PCR assay  
The ultra-short E6*I mRNA reverse transcription (RT)-PCR assay was performed 
using the QuantiTect® Virus Kit (Qiagen, Hilden, Germany) as described previously 
131
. The kit offers highly sensitive RT-PCR analyses of viral nucleic acids and internal 
controls using sequence-specific probes. 
Primers that amplify an ultra-short 65-75 bp sequence of cDNA across the E6*I splice 
site for 20 HPV types, allowing the detection of 12 high-risk and 8 possibly high-risk 
HPV types. As internal quality control, splice-specific detection of cellular 
housekeeping-gene ubiquitin C cDNA was included.  
One μl of extracted RNA was applied for cDNA synthesis. Biotinylatedamplimers 
generated by PCR (HPV E6*I and ubiquitin C) were hybridized to type- and splice site-
specific oligonucleotide probes coupled to fluorescence-labeled polystyrene beads 
(Luminex suspension array technology) detectable with Luminex readers. In total 2 
different bead sets were used; one for E6*I splice site specific probe for each HPV type 
tested, and one for the ubiquitin C probe. Results were expressed as MFI of at least 50 
beads per set. To define positive results a cut-off value of 5 net MFI was applied. 
Analytical sensitivity determined by a 10-fold in vitro transcript dilution series, was at 
or below 100 transcript copies per reaction per 18 HPV (16, 18, 31, 33, 35, 39, 45, 51, 
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52, 56, 58, 59, 26, 53, 66, 68, 73 and 82) types and Ubiquitin C; specifically for the 
types 16 and 58 sensitivity was 10 transcript copies per reaction. 
 
 
3.8 Multiplex serology  
Multiplex serology (MS) is a high-throughput technology that allows the quantification 
of specific antibodies against up to 100 different antigens in parallel. The method is a 
glutathione S-transferase (GST) capture immunosorbent-based assay in combination 
with fluorescent bead technology as previously described 167-169. The method was 
performed for the early (E6, E7) and late (L1) proteins of high-risk HPV types 16, 18, 
31, 33, 45, 52 and 58 and low-risk types 6 and 11and for the E1, E2, and E4 proteins of 
types 16 and 18. 
Briefly, the method employs beads derivatized with glutathione, thereby permitting 
bead-mediated in situ affinity purification of viral antigens bacterially expressed as 
GST fusion proteins. Spectrally distinct bead sets carrying different viral antigens were 
individually washed and subsequently mixed. Each diluted serum in preincubation 
buffer and mixed beads were combined and incubated. Bound antibodies were detected 
with biotinylated anti-human secondary antibody (goat anti-human IgA, IgM, IgG 
(H+L), Dianova) and fluorescent detection conjugate (streptavidin-R-phycoerythrin, 
Molecular Probes). Reporter fluorescence of the beads was determined bya Luminex-
100 analyzer,and expressed as median fluorescence intensity (MFI) of at least 100 
beads per set per serum. For background determinationbeads were loaded with GST 
alone. 
The cut-off was determined as described in 170, 171. Briefly, a reference set of samples 
belonging to a self-declared sexually naive and genital HPV DNA negative group, was 
used. For each of the HPV seromarkers the cut off was defined as the mean of the MFI 
values from the reference samples + 5 standard deviations. 
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3.9 Immunohistochemistry 
The expression level of cellular proteins p16INK4aand pRb was analyzed by 
immunohistochemistry (IHC) using monoclonal antibodies. The staining principle is 
shown in Figure 9. 
 
 
Figure 9.Immunohistochemistry staining procedure. a) sections are incubated with the primary antibody 
after previous blocking with normal horse serum; b) after washing steps the sections are incubated with a 
secondary antibody peroxidase-conjugated; c) development with a peroxidase substrate (adapted from 
Vectorlab website 172. 
 
 
The IHC staining was processed manually as follows: sections were deparaffinized in 
xylene, rehydrated in a descending alcohol series, boiled in 10 mmol/l of citrate buffer 
for 30 min to unmask antigens, blocked in normal serum (ImmPRESSKit ready to use) 
for 20 min, and then incubated with the primary antibody. Further, sections were 
incubated with the secondary antibody (Vector: ImmPRESS Kit mouse, ready to use) 
for 20 min at room temperature, developed with 3,3′-diaminobenzidine (DAB) from 3 
to 5 min, counterstained with hematoxylin, dehydrated in an ascending alcohol series, 
and covered with a coverslip embedded with Eukitt (section 3.2). Primary antibodies 
used were: CINtec for p16INK4a (V-kit, MTM laboratories, Heidelberg, Germany) 
incubation for 75 min at room temperature; pRb (NCL-RB, Novocastra, Newcastle 
upon Tyne, United Kingdom) incubated for 60 min at room temperature in dilution 
1:35. 
Stained sections were evaluated by two investigators (L.B. and D.H.) by scoring the 
percentage of stained tumor cells over the whole tumor section. Discordant cases were 
discussed together at the microscope and a consensus was reached. For the simplicity 
of evaluation only two categories of deviation from normal expression were assigned; 
protein down-regulation or up-regulation.  
a) b) c) 
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The cut-off for protein up- or down-regulation was determined by evaluation of the 
staining intensity and stain distribution  in healthy uvula analyzed in parallel with 
cervical carcinoma (CxCa) tissues 135. Nuclear and cytoplasmic p16INK4a was absent in 
the healthy uvula and up-regulated in the CxCa. Nuclear pRb was abundant in the 
healthy uvula, and expressed in < 25% of the tumor cells of the CxCa. Tumor sections 
with CxCa-like staining pattern and intensity were classified as down-regulated pRb. 
 
 
3.10 OncoE6 kit (Arbor Vita) 
The OncoE6TM Oral Test allows the detection of the E6 oncoprotein of high-risk HPV 
types 16 and 18 in different types of samples (like, saliva, cervical smears, swab, 
homogenized fresh tissues) 173, 174. 
 
 
   Figure 10.Principle of the assay (source: Arbor Vita Corporation) 
 
The assay was applied to fresh frozen tumor sections (see section 3.1.1). Figure 13 
shows the kit's principle assay. The specimen was prepped sequentially by treating the 
swab with a lysis solution (15 minutes), a condition solution (15 seconds), and then 
clarifying the specimen solution using a table-top microcentrifuge (10 minutes at 8000 
rpm). A 200 µl aliquot of the clarified specimen solution is then transferred into a vial 
with lyophilized detector monoclonal antibody alkaline–phosphatase conjugate. The 
test strips with immobilized capture monoclonal antibodies are inserted into specimen-
conjugate mixture and the solution is permitted to migrate up the strip by capillary 
action. After 55 minutes, the tests are washed for 12 minutes and then immersed into 
the developing solution containing the alkaline–phosphatase substrate 
(NitroblueTetrazolium). After 15 to 25 minutes (depending on the ambient 
temperature), the test unit is removed from the developing solution vials and placed on 
Methods 
 
41 
 
 
a reading guide, allowing for visual inspection. Appearance of one or more test lines 
indicates E6 oncoprotein of the corresponding HPV type present in the initial cervical 
swab specimen. 
The analytical sensitivity for E6 protein for HPV type 16 was determined by using 
dilution series (from 105 to 100cells) of the cell line MRI-H186 (HPV16 positive) 
combined with 106 cells from the cell line HEK293T (HPV negative), to mimic the 
tumor sample condition. One diploid cell contains 6.66 pg of DNA. The mean DNA 
concentration from our samples measured by a spectrophotometer (Nanodrop ND1000) 
formula 50 x OD260)) was 50 ng/μl (50 ng in 1 µl). Therefore in 50 ng (5 x 104 pg) of 
DNA contains approximately 7575 cells in 1 µl volume. The assay uses a lysate of 200 
µl aliquot thus, we expect approximately 1.5 x 106 cells (= 7575 cells x 200 µl).  
 
 
3.11 Statistical analyses 
Patient and tumor characteristics were evaluated in relation to their HPV DNA and 
RNA status. Follow-up was determined as the time-difference between the date of the 
last clinical examination and the diagnosis date. 
Overall survival (OS) was measured as the time from the date of primary tumor 
diagnosis to the date of death. Survival times of patients who were alive at date of last 
follow-up were censored. 
Progression-free survival (PFS) time was calculated from the date of primary tumor 
diagnosis to the date of the first local recurrence, new lymph node or distant metastasis, 
second primary carcinoma. Survival times of patients who were alive at the date of last 
follow-up or dead due to HNSCC-unrelated tumor were censored. The method of 
Kaplan and Meier was used to estimate survival distributions. HPV-associated and 
HPV negative groups were compared using the log-rank test. In all statistical tests a P 
value of 0.05 or below was considered as statistically significant. The statistical 
analyses were carried out using SPSS, version 17, as well as the software Sigmaplot. 
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4. RESULTS 
Two-hundred-forty-seven (247) consecutive patients with newly detected head and 
neck cancer were enrolled in the North-East area of Italy between 2003 and 2012. 
Tissue samples (247 fresh tumor biopsies and 53 FFPE blocks) were available for all 
patients and serum samples for only 102 (41%) since serum collection was possible 
only in the last three years of the project (2010-2012). All tumor samples of the patients 
were firstly analyzed for HPV DNA status. HPV DNA positive tumors and some HPV 
DNA negative tumors as negative controls were further characterized for viral load, the 
presence of viral transcripts (E6*I), up-regulation of p16INK4a and down-regulation of 
pRb, presence of the oncoprotein E6. HPV seromarkers were determined for all 
available sera. 
 
 
4.1 Clinicopathologic characteristics of the study population 
Of the enrolled 247 head and neck tumor patients 76% were males, in a ratio 3:1 
compared to females (24%) and a median age at diagnosis of 66 years (range 27-95) 
(Table 1). 
More than 50% of the patients were current and another 15% were past tobacco 
smokers. Current alcohol consumption was reported by 53% of patients and another 
12% had this habit in the past. 
Of the tumors 39% were in the larynx, 26% each in the oropharynx and the oral cavity, 
and 10% in the hypopharynx. Small-sized (T1-T2) tumors were present in 50% of the 
patients and lymph nodes were involved in 52%. Only 1% of patients had distant 
metastases. 
The patients received treatment with various modalities: 35% underwent surgery alone, 
29% received radio- and/or chemo-therapy without surgery and35% in combination 
with surgery. 
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Table 1.Clinicopathologic characteristics of all study participants and stratified by HPV DNA status 
 
  Total HPVDNA
_
 HPVDNA+  
Characteristics  N= 247 N= 226 N= 21  
Age (Median, y)  65 65 68  
 
    
 
 
 N (%) N (%) N (%) P-value 
Gender Male 188 (76) 173 (76) 15 (71) 0.3 
 Female 59 (24) 53 (24) 6 (29)  
Tobacco Never 79 (32) 69 (31) 10 (48) 0.2 
 Former 34 (15) 30 (13) 4 (19)  
 Current 124 (50) 118 (52) 6 (28)  
 Missing 10 (4) 9 (4) 1 (5)  
Alcohol Never 75 (30) 69 (30) 6 (28) 0.6 
 Former 29 (12) 26 (11) 3 (14)  
 Current 131 (53) 120 (53) 11 (53)  
 Missing 12 (5) 11 (5) 1 (5)  
Localization Oral cavity 63 (26) 62 (28) 1 (5)  
 Oropharynx 63 (26) 46 (20) 17 (81) 0.0001 
 Larynx 96 (39) 95 (42) 1 (5)  
 Hypopharynx 25 (10) 23 (10) 2 (9)  
Tumor size T1-T2 124 (50) 113 (50) 11 (52)  
 T3-T4 123 (50) 113 (50) 10 (48)  
Lymph nodes N0 128 (52) 123 (54) 5 (24)  
 N+ 119 (48) 103 (46) 16 (76) 0.011 
Metastasis M0 244 (99) 223 (99) 21 (100)  
 M+ 3 (1) 3 (1) 0  
Therapy Surgery only 87 (35) 84 (37) 3 (14)  
 RT and/or CT 71 (29) 61 (27) 10 (48)  
 Surgery and RT and/or CT 87 (35) 79 (35) 8 (38)  
 Missing 2 (1) 2 (1) 0  
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4.2 HPV DNA prevalence and genotyping 
H&E1 stained slides showed presence of >80% tumor cells in all tumor biopsies. 
Directly neighboring sections were analyzed for presence of mucosal HPV DNA 
genotypesby two different methods (see section 3.4.1-2), MY09/11-RFLP and 
BSGP5+/6+-PCR/MPG51. Both techniques target the L1 region of HPV and amplify a 
broad spectrum (49 and 51 types, respectively) of HPV types 127, 162. 
 
Good DNA quality, as defined by positivity for the cellular β-globin gene was 
confirmed for all the tested samples. The MY09/11-RFLP assay was performed in 223 
(90%) of the tumor biopsies and identified 18 (8%) single HPV infections (HPV 
DNA+) of which 17 were HPV16 and 1 was HPV58. 
The BSGP5+/6+-PCR/MPG51, a more sensitive method, was used in 138 (60%) of the 
tumorsand identified 10 (7%) single HPV infections of which 9 were HPV16 and 1 was 
HPV58. 
 
Agreement between the two HPV genotyping methods was evaluated on 114 samples. 
Six cases were concordantly positive, 105 cases concordantly negative, two cases 
positive only with BSGP5+/6+-PCR/MPG51and one case positive with MY09/11-RFLP 
only, resulting in a ĸ-value of 0.8. The same HPV genotype was identified in each of 
the concordantly positive cases. The analytical sensitivity of the BSGP5+/6+-
PCR/MPG51 is ~10 fold higher 127 than the MY09/11-RFLP 128. Thus, the 2 cases 
positive only by BSGP5+/6+ -PCR/MPG51were considered as true positives and 
included in the subsequent analyses. The single sample HPV-+ only by MY09/11-
RFLPwas HPVRNA-and therefore considered as a false positive. 
 Figure 11. Distribution of HPV DNA genotyping results 
carcinoma (HNSCC) patients from North-Eastern Italy
by BSGP5+/6+-PCR/MPG51 and/or MY09/11-RFLPin tumor tissues of 247 head and neck squamous cell 
. 
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Overall HPV DNA prevalence was 8.5% (21/247) (Figure 12). No multiple infections 
were identified. The most frequent HPV genotype was type 16 (95%, 20/21 HPV 
DNA+ cases), while HPV58 was identified once (5%) 
Oropharynx showed the highest HPV DNA prevalence (27%, 17/63), followed by 
hypopharynx (8%, 1/25), oral cavity (2%, 1/63) and larynx (1%, 1/96). 
 
 
4.3 Viral load 
HPV viral load was determined by HPV16qPCR (only for samples HPV16 DNA+) and 
by BSGP5+/6+-PCR/MPG51 ( for all HPV DNA+ types). 
By HPV16qPCR, the viral load was evaluated in 17 samples and resulted high in 13 
tumors with a median of 2.6 (range 0.6 – 1000) copies per cell, negative in 3 tumors 
and invalid in one tumor (no β-globin copies  detected) (Table 2). The cut-off for high 
viral load was > 0.5 viral genome copies per cell 157. 
For 9 HPV16 DNA positive cases with valid HPV16 qPCR results, viral load was also 
estimated by the BSGP5+/6+-PCR/MPG51as described previously 127. Using a 
normalized HPV/β-globin MFI ratio of 0.0007 as cut-off, high viral load was estimated 
in 7 (6 type 16 and 1 type 58) and low viral load in two tumors. One viral load 
determination was discordant between the two methods with high (ratio 0.000748) in 
BSGP5+/6+ -PCR/MPG51 assay and negative in qPCR (Table). 
 
 
4.4 RNA analyses 
RNA from 18 HPV DNA positive tumors was available for HPV16 E6*I and ubiquitin 
C transcription analysis. RNA from 27 HPV DNA negative tumors served as negative 
controls. The presence of HPV58 E6*I transcript was tested only in the HPV58 DNA 
positive sample.  
All the 45 RNA samples were ubiquitin C RNA positive and thus valid. The 27 HPV 
DNA negative samples showed no HPV16 transcripts. 
Among the 18 HPV DNA positive samples, 4 were negative and 14 (78%) showed 
expression of type-concordant HPV E6*I mRNA. The single case identified as HPV 
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DNA positive for type 58 showed presence of HPV58 and absence of HPV16 
transcripts (Table 2). 
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Table 2. HPV DNA+ (positive) tumors,  the types identified, their viral load by HPV16 qPCR (HPV16 VL) and by MPG (HPV MPG VL), presence of HPV RN+ 
(positive), oncoE6 protein, p16INK4a up-regulation and pRb down-regulation. 
 
Tumor 
   ID 
Anatomic 
site 
HPV 
DNA+ 
HPV16 VL CO > 
0.5 copies/cell 
HPV MPG  
VL  CO > 
0.0007 
HPV 
RNA+ 
oncoE6 
protein 
p16INK4a   
up-regulation 
pRb  
down-
regulation 
49 Oropharynx 16 high 
 
16 
  
no 
208 Oropharynx 16 high 
 
16 
 
yes yes 
64 Hypopharynx 16 high 
 
no 
 
no no 
327 Oropharynx 16 high 
 
16 
 
yes no 
521 Oropharynx 16 high high_16 16 3a 
  159 Oropharynx 16 high high_16 16 3 yes yes 
14 Oropharynx 16 high high_16 16 3 
  58 Oropharynx 16 high 
 
16 
 
yes yes 
196 Larynx 16 high high_16 16 4 yes yes 
12 Oropharynx 16 high high_16 16 4 yes no 
103 Oropharynx 16 high 
 
16 
 
yes no 
44 Oropharynx 16 high high_16 16 2 
  498 Oropharynx 16 high high_16 16 3 
  32 Oropharynx 16 negative high_16 no 0 
  65 Hypopharynx 16 negative low_16 no 0 
  23 Oropharynx 16 negative 
 
no 
 
no 
 399 Oropharynx 58 negative high_58 58 
 
yes yes 
56 Oropharynx 16 
      
 30 Oropharynx 16 
      313 Oropharynx 16 
      17 Oral cavity 16 invalid 
 
16 
 
yes yes 
 
aoncoE6 protein staining intensity: 4= very strong positive, 3= positive, 2= weak positive and 0= negative. 
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Assuming that all HPV DNA negative samples were negative for E6*1 mRNA, the 
overall prevalence of HPVDNA+RNA+ tumors was 6% (14/244), and that of HPV 
DNA+RNA- tumors was 1.7% (4/244) (Figure 15). Compared to the other head and 
neck anatomical sites, oropharynx with 20% (12/61)showed the highest prevalence of 
HPVDNA+RNA+ tumors, followed by 1.6% (1/63) in the oral cavity, 1% (1/95) in the 
larynx, and 0% (0/25) in the hypopharynx. 
 
 
 
Figure 12. Overall and site specific HPV DNA and RNA prevalence among all head and neck tumors 
and stratified by anatomical site. 
Overall, 247 tumors were analyzed for HPV DNA, 63 from the oropharynx, 63 from the oral cavity, 96 
from the larynx, and 25 from the hypopharynx. Of the HPVDNA+ tumors 18 samples were analyzed for 
HPV RNA, while for 3 cases (2 from oropharynx and 1 from larynx) could not be analyzed. 
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4.5 OncoE6 protein expression 
4.5.1 Analytical sensitivity of HPV16 E6 detection 
The analytical sensitivity of the OncoE6 protein assay was determined in 10-fold dilution series 
of the HPV16 positive cervical carcinoma cell line MRI-H 186 with and without a constant 
amount of the HPV negative cell line HEK 293T as background. HPV16 E6 protein was 
detected in as little as 5x103 cells MRI-H 186 both with and without background HEK 293T 
cells (Table 3). 
 
Table 3. HPV16 E6 detection limit of the OncoE6 assay determined in serial dilution of HPV16+ MRI-
H cells (in numbers, N) without (A) and with (B) a background of HPV16- HEK 293T cells. 
 
A) MRI-H 186 
cells (N) 
HEK 293T 
cells (N) 
Staining 
intensityb 
B) MRI-H 186 
cells (N) 
HEK 293T 
cells (N) 
Staining 
intensityb 
 5x106 0 5  5x106 0 5 
 5 x 105 0 4  5 x 105 0 4 
 5x104 0 2  5x104 0 3 
 5x103 0 1  5x103 0 1 
 5x102 0 0  5x102 0 0 
bStaining intensity: 5= very strong positive, 4= strong positive, 3= positive, 2= weak positive, 
1= very weak positive and 0= negative. 
 
 
 
 
4.5.2 E6 oncoprotein in HNSCC 
HPV16 E6 protein was detected in lysates from 7 out of 9 fresh frozen HPV16 DNA 
positive HNSCC tissues (Table 2). The other two HPV16 DNA positive HNSCC and 
the one HPV negative HNSCC used as specificity control did not show HPV16 E6 
protein. None of the HNSCC lysates analyzed reacted positive for HPV18 E6 protein. 
All 7 HPV16 E6 positive HNSCC (Tumor ID, 521, 159, 14, 196, 12, 44 and 498, in 
Table 2) were positive for E6*1 RNA and had high viral loads, while the two E6 
protein negative but HPV16 DNA positive tumors showed no E6*I RNA and had low 
viral loads. 
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4.6 Expression levels of cellular proteins p16INK4a and pRb 
Expression of p16INK4a and pRb was evaluated by immunohistochemistry on 54 and 48 
FFPE sections, respectively. 
Out of 54 cases, 10 samples showed an up-regulation of p16INK4a, 42 cases showed a 
normal low expression and 2 cases were excluded from the analyses (1 case was not 
possible to evaluation and the other one the tumor cells were absent). Relating p16INK4a 
expression to the HPV DNA status (see Table 4), 9 cases HPV DNA positive showed 
an up-regulation for p16INK4a ,while the other 2 cases showed down-regulation. Among 
the HPV DNA negative group, 40 cases had p16INK4a down-regulated and only 1 case 
showed up-regulation of the protein.   
pRb expression was tested in 48 slides but could be evaluated in 47 (1 case was 
excluded due to absent tumor cells). Seven (7) cases showed pRb down-regulated and 
40 had up-regulation of the protein. Among the HPV DNA positive cases 6/11 showed 
pRb down-regulation, while in the HPV DNA negative group pRb up-regulation was 
observed in 35/36 cases. 
 
Table 4. Expression of p16INK4a in (A) and pRb in (B) related to the HPV DNA positive and negative 
tested samples given in numbers (N).  
A) 
 
p16INK4a 
  up-regulated  down-regulated  
HPV DNA positive  (N=11) 9 2 
HPV DNA negative  (N= 41) 1 40 
Total= 52 10 42 
   
B) 
 
pRb 
  down-regulated up-regulated 
HPV DNA positive  (N= 11) 6 5 
HPV DNA negative  (N= 36) 1 35 
Total= 47 7 40 
 
 
Ten (10) cases HPV DNA positive were evaluated for expression of  both p16INK4a and 
pRb proteins (Table 2). Six (6) out of 10 cases had up-regulated p16INK4a and down-
regulated pRb. 
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4.7 HPV antibodies 
All 102 sera obtained from patients with HNSCC of the oropharynx (N= 22), the larynx 
(N= 31), the hypopharynx (N= 10) and the oral cavity (N= 39) were analyzed by bead-
based multiplex serology for antibody reactivity against the E6, E7 and L1 proteins of 
the 7 hr-HPV types 16, 18, 31, 33, 45, 52 and 58 and against the E1 and E2 proteins of 
HPV types 16 and 18. High cut-off values were applied to classify sera as antibody-
positive since previous studies had shown strong associations of HPV antibodies with 
oropharyngeal cancer 108, 171, 175, 176 with strong reactions to the individual HPV proteins 
(M. Pawlita, personal communication). 
 
All sera from the 7 patients with HPV-driven (HPV DNA+RNA+) tumors (6 HPV16, 1 
HPV58; 6 oropharynx, 1 (tumor 196) supraglottic larynx) showed strong positive 
antibody reactions with HPV E6 and E7 proteins, 5/7 (71%) also with E2 and L1, 
respectively, and still 4/7 (57%) with E1 (Table 5; Emax and L1max; Table 6). In 
contrast, among the 94 patients with HPV DNA- (negative) HNSCC antibody-positive 
reactions with these proteins were rare and weaker (Table 5), leading to prevalences of 
7% or less for the early proteins and 14% for L1 (Table 6). When a universal super 
strong cut-off of 2000 MFI was applied, prevalences in patients with HPV-driven 
tumors for the early protein antibodies remained constant but in the patients with DNA- 
tumors declined to 3% or less. 
 
In patients with HPV-driven HNSCC seropositivity with early proteins frequently 
showed cross-reactions with the homologous proteins of the 6 other HPV types, most 
common for E7 (mean number of E7 proteins recognized 2.9, range 1-5) followed by 
E6 (mean 1.7, range 1-4) while among the HPV DNA- tumor patients positive sera 
recognized always only the protein of one HPV type (Table 5). This multiple reactivity 
was also visible for the E1 and E2 proteins (data available only for HPV types 16 and 
18) with means of 1.5 and 1.8 among the patients with HPV-driven tumors and 1.3 and 
1.0 among the HPV DNA- tumor patients. 
Patients with HPV-driven tumors also recognized more of the early proteins than those 
with HPV DNA- tumors. When a score of 1 was given to each positive reaction with 
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one of the 4 different early proteins, the cumulated early antibody score (score E-Ab) 
was 2 or greater for all 7 patients with HPV-driven tumors while only one of the HPV 
DNA negative tumor (tumor 489) patients had a E-Ab score of 2. With the super-
stringent cut-offs of 2000 MFI the E-Ab scores in the HPV-driven tumor patients group 
did not change, as well as the E-Ab score of 2 of the HPV DNA negative tumor (tumor 
489) patient. 
Type concordance of the strongest serological reaction to the individual proteins with 
HPV type by DNA was high. All 6 patients with HNSCC driven by HPV16 showed the 
strongest reactions with the E6 and E7 proteins of HPV16. The patient with the 
HPV58-driven tumors reacted strongest with E7 of HPV58 but the reaction with 
HPV33 E6 was stronger than that with HPV58 E6.  
 
The serum of the patient with the HPV16 DNA+ tumor (Tumor ID 313) for which no 
other molecular markers could be analyzed demonstrated strong antibody reactivities 
with all four early proteins of HPV 16, suggestive for the presence of an HPV16-driven 
tumor. 
The serum of the patient with the DNA- tumor 489 was double positive with E6 and E1 
of HPV16 (E-Ab score of 2), even with the super-stringent cut-off, a serological pattern 
suggestive of the presence of an HPV-driven tumors. It should be attempted to analyze 
the tumor for HPV16 E6*I RNA and the cellular surrogate markers of HPV 
transformation both in the currently available tumor as well as to attempt to obtain a 
second tissue sample of this tumor for these analyses to surely exclude a false-negative 
HPV-genotyping result. 
In the molecularly well-characterized HNSCC patient series analyzed here, HPV 
serology using an E-Ab score of 2 demonstrated a sensitivity of 100% for detection of 
patients with HPV-driven tumors and a specificity of about 99%. 
 
 
 
 
Results 
 
54 
 
 
Table 5. Antibody reactivity of  HNSCC patient’s seraa  with early and late proteins of  hr-HPV types ordered by HPV status of the tumor. 
 
      
HPV Antibody reactivity (Median Fluorescence Intensity, MFI) 
HPV type 
E-Ab 
Score protein E6 E7 E1 E2 L1 E6 E7 E1 E2 L1 
Tumor   Serum type max max max max max   16 18 31 33 45 52 58   16 18 31 33 45 52 58  16 18  16 18   16 18 31 33 45 52 58 
ID DNA RNA ID cut-off 800 1000 1400 1400 1000 800 800 800 800 800 800 800 800 800 800 800 800 800 800 1400 1400 1400 1400 1000 1000 1000 1000 1000 1000 1000 
327 16 16 329 2
b
 13290
c
10992 151 437 531 13290 129 128 1265 88 147 618 10992 108 6806 8486 936 3225 2656 151 133 115 437 409 255 320 411 255 397 531 
159 16 16 222 4 12519 4079 2780 13349 1076 12519 91 101 94 48 101 100 4079 167 267 1200 81 64 284 2780 183 13349 8000 1076 195 275 313 150 293 335 
208 16 16 210 4 9219 7651 7737 8344 7471 9219 234 212 3616 986 187 1758 7651 1 53 98 11 23 1 7737 2425 6579 8344 7471 777 3720 1927 1215 2930 1927 
196 16 16 198 3 8864 8859 70 5763 2143 8864 87 94 235 62 115 173 8859 1 5061 3080 155 73 1523 62 70 5763 448 2143 176 276 312 168 316 430 
498 16 16 500 4 8283 4932 6016 8080 1860 8283 40 68 24 27 43 35 4932 1 3490 1326 1 22 71 6016 1094 7081 8080 1860 1060 911 284 1104 530 266 
521 16 16 523 4 6332 3044 6813 7083 880 6332 239 186 112 499 298 132 3044 88 28 263 15 35 27 6813 789 7083 3688 880 119 189 234 78 310 158 
399 58 58 401 2 2374 3278 107 188 2136 644 70 70 2374 38 152 1855 1138 1 2087 2020 113 435 3278 107 76 73 188 2136 323 1168 1798 860 1962 1742 
313 16     315 4 7769 7475 6107 7593 587  7769 89 491 344 89 242 302  7475 1 3120 248 6 823 22  6107 1721 7593 4434  570 239 587 353 234 432 371 
241 - 243 1 3367 75 54 318 317 51 66 85 68 3367 90 706 39 75 38 25 15 38 37 38 54 71 318 317 136 300 217 98 241 277 
489 - 491 2 2571 65 4527 124 187 2571 27 37 55 44 40 86 65 1 19 17 1 19 18 4527 2219 41 124 187 111 145 96 126 139 109 
307 - 309 1 2526 76 21 192 252 43 55 2526 56 89 69 89 25 1 30 59 1 76 65 21 17 51 192 176 252 142 152 188 176 235 
342 - 344 1 1243 245 272 436 541 68 138 1243 157 105 165 104 245 35 37 39 17 43 26 272 73 328 436 479 237 505 541 236 369 504 
357 - 359 1 1230 301 251 1040 1793 287 455 607 342 351 678 1230 202 106 167 76 101 301 145 64 251 437 1040 1232 1023 1431 1105 990 892 1793 
187 - 189 1 1213 26 31 278 240 38 68 86 1213 83 91 670 17 1 13 11 1 26 6 30 31 60 278 195 124 188 208 118 195 240 
492 - 494 1 814 1168 157 1263 684 52 71 814 75 27 77 116 1168 3 148 106 239 383 45 56 157 403 1263 307 684 513 638 592 438 505 
274 - 276 1 217 3931 130 306 606 214 103 217 119 58 115 105 3931 1 49 34 16 101 31 35 130 90 306 503 223 481 366 209 606 467 
277 - 279 1 143 3660 42 183 180 36 57 65 143 81 71 73 3660 80 21 52 18 26 19 31 42 89 183 163 87 174 141 87 158 180 
467 - 469 1 158 1515 83 297 279 54 133 92 76 49 158 149 1515 16 30 83 13 35 17 83 81 177 297 262 168 201 215 162 226 279 
190 - 192 1 103 1222 49 227 257 62 103 80 83 59 85 91 34 66 25 9 239 127 1222 34 49 81 227 186 210 247 239 125 229 257 
512 - 514 1 221 1007 82 182 249 25 100 152 69 44 221 190 160 1007 51 29 62 41 16 67 82 72 182 236 200 206 249 132 225 202 
211 - 213 1 97 39 6697 309 257 65 78 87 78 97 82 93 33 1 39 20 10 33 18 728 6697 112 309 241 189 243 250 140 209 257 
147 - 149 1 128 64 78 6457 386 59 92 97 88 61 128 103 37 1 44 30 55 64 40 60 78 86 6457 329 136 271 386 139 282 308 
289 - 291 1 136 90 2514 727 372 58 119 119 81 85 111 114 59 1 38 13 32 90 18 2514 77 727 443 345 81 301 283 223 283 372 
460 - 462 0 121 49 442 217 2428 43 35 121 52 37 73 56 26 1 32 1 1 49 27 442 43 37 217 180 83 164 89 69 127 2428 
298 - 300 0 168 54 47 304 1869 26 168 85 87 52 96 77 29 1 29 54 53 39 47 47 32 63 304 209 149 231 218 138 270 1869 
476 - 478 0 80 58 128 183 1829 16 43 80 55 28 61 57 58 1 12 34 1 12 24 128 47 82 183 1829 98 181 137 79 125 155 
509 - 511 0 63 33 55 206 1674 4 23 37 27 8 43 63 9 1 12 33 8 6 1 51 55 41 206 687 1674 698 618 85 273 429 
354 - 356 0 175 84 53 455 1589 70 86 104 79 69 100 175 33 84 34 24 25 56 38 43 53 455 386 281 283 1589 262 197 293 399 
381 - 383 0 300 225 112 823 1588 109 236 300 251 169 267 267 65 1 81 225 34 46 54 56 112 239 823 1588 824 511 840 682 909 626 
336 - 338 0 70 256 40 332 1581 17 70 55 30 44 25 48 97 1 36 13 1 256 1 26 40 332 186 1581 418 397 190 555 373 220 
263 - 265 0 249 828 67 402 1350 37 115 114 116 82 249 150 34 251 67 828 31 39 19 53 67 119 402 1350 711 820 708 1100 1020 608 
235 - 237 0 121 46 75 426 1280 36 83 90 72 67 82 121 16 1 28 9 11 46 14 47 75 84 426 1072 1061 757 412 1280 577 423 
178 - 180 0 456 384 332 926 1212 15 157 209 130 1 456 333 27 1 1 384 1 1 1 332 211 118 926 673 426 896 1131 715 1212 1191 
202 - 204 0 739 69 347 497 1187 739 129 139 161 169 142 147 61 69 41 18 44 24 33 53 347 162 497 516 1187 396 341 220 350 367 
181 -     183  0 281 550 173 563 1115  144 181 233 176 110 182 281  550 34 41 134 38 39 30  173 90 139 563  595 446 884 564 358 503 1115 
a
 A total of 102 sera were analyzed,  In addition to the 7 sera from all HPV DNA+RNA+ patients and the serum of the single patient with a HPV DNA+ tumor (no other molecular markers analyzed) of the 94 sera from HPV DNA- tumor patients only the 27 sera with at least one positive 
antibody reaction are shown;  bE-Ab score, number of E-proteins with at least one positive reaction;  c reactions above cut-off are highlighted by colour, in blue the highest reaction for a given protein, in red other, less strongly positive reactions with the same protein from other HPV types 
for the HPV type. 
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Table 6. Antibody prevalence against HPV early and late proteins in HNSCC patients with HPV-driven 
and HPV DNA- tumors applying strong and super strong cut-offs for classification. 
 
    Protein  E6   E7   E1   E2   L1   
Stringent cut-off Cut-off (MFI) 800 1000 1400 1400 1000 
    total N+ % N+ % N+ % N+ % N+ % 
HPV-driven 7 7 100 7 100 4 57 5 71 5 71 
  DNA- 94 7 7 6 6 3 3 1 1 13 14 
    Protein  E6   E7   E1   E2   L1   
Super stringent cut-off  Cut-off (MFI) 2000 2000 2000 2000 2000 
    total N+ % N+ % N+ % N+ % N+ % 
HPV-driven 7 7 100 7 100 4 57 5 71 3 43 
  DNA- 94 3 3 2 2 3 3 1 1 1 1 
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4.8 Definition of the HPV-driven HNSCC 
Positivity for DNA and E6*I mRNA viral transcripts was primarily used to define a 
tumor as HPV-driven (Table 7). The other markers were then analyzed to evaluate their 
efficacy as additional or alternative biomarkers for HPV causality.  
E6*I mRNA positivity showed concordance with high viral load (13/14, 93%), 
presence of E6 protein (7/7, 100%) and HPV E6+E7 type concordant seropositivity 
(8/8, 100%). While, concordance of E6*I mRNA positivity with up-regulated p16INK4a 
and down-regulated pRb was observed only in 6 out of 10 tested (60%) samples. 
Based on the serological results (E-Ab score of 4) we defined as HPV-driven one 
additional case (Table 8, Tumor ID 313) that could not be tested for RNA transcripts.  
On the contrary one other case, belonging to the hypopharyngeal site (Tunor ID 64, 
Table 8) showed a high viral load but showed negativity for the presence of viral 
transcript and thus was considered as non HPV-driven.  
 
Overall, out of 21 HPV DNA positive tumors, 15 were defined as HPV-driven, 4 as 
non-HPV-driven, while for the 2 remaining cases no tumor or serum specimen was 
available to perform the additional analyses (n.d.) (Table 7).  
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Table 7. HPV DNA and the other analyzed markers (HPV16 viral load, RNA, up-regulation of p16INK4a 
and down-regulation of pRb and HPV16E6 protein). 
 
 
 
 
 
 
4.9 Statistical analyses 
4.9.1 Correlation between clinicopathologic parameters and HPV-driven 
Statistical analyses performed among HPV status (DNA positive and negative cases) 
and each of the parameters gender, age, tobacco, alcohol resulted not statistically 
significant (P> 0.005) see Table 1. The only significant correlation was observed 
between HPV status and the site of oropharynx (P< 0.0001). 
 
4.9.2 Survival analyses 
Patients were enrolled between 2003 and 2012; 95 (38.46%) were dead (53 due to the 
primary HN-tumor, 20 for a second malignancy, 22 not tumor related) and 152 
(61.54%) were alive. Follow-up median time was 20 months (range, 1-121 months). A 
  
Tumor 
ID 
Anatomic 
site 
HPV 
DNA+ 
HPV 
RNA+ 
HPV  
viral load 
oncoE6 
protein 
up-regulated p16INK4a and 
down-regulated pRb 
HPV E6+E7 
Ab reactivity 
HPV-
driven 
49 Oropharynx 16 16 high_16 yes 
208 Oropharynx 16 16 high_16 yes yes yes 
327 Oropharynx 16 16 high_16 no yes yes 
521 Oropharynx 16 16 high_16 + yes yes 
159 Oropharynx 16 16 high_16 + yes yes yes 
14 Oropharynx 16 16 high_16 + yes 
58 Oropharynx 16 16 high_16 yes yes 
196 Larynx 16 16 high_16 + yes yes yes 
12 Oropharynx 16 16 high_16 + no yes 
103 Oropharynx 16 16 high_16 no yes 
44 Oropharynx 16 16 high_16 + yes 
498 Oropharynx 16 16 high_16 + yes yes 
399 Oropharynx 58 58 high_58 yes yes yes 
17 Oral cavity 16 16 invalid yes yes 
313 Oropharynx 16         yes yes 
64 Hypopharynx 16 no high_16 no no 
32 Oropharynx 16 no negative - no 
65 Hypopharynx 16 no negative - no 
23 Oropharynx 16 no negative no 
56 Oropharynx 16 n.d 
30 Oropharynx 16 n.d 
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negative event (local or distant recurrent HN-tumor) was recorded for 93 (37.65%) 
patients. 
Considering all head and neck anatomical sites together, no significant difference in 
overall survival (OS) was observed between the HPV-driven group compared to the 
HPV negative (HPV DNA negative and HPV DNA positive RNA negative) ones (p= 
0.67) (Fig. 13A.). Instead, a better trend of progression free survival (PFS) was 
observed in the HPV-driven patients after 40 months of follow-up, but still not 
statistically significant (Fig. 13 B.). 
Restricting the analyses to the oropharyngeal site, a trend of better survival (OS and 
PFS) in the HPV-driven group compared to the HPV negative patients was observed 
(Figure 13 C and D). 
 
 
  
Figure 13. Overall survival (OS) and progression free survival (PFS) in head and neck anatomical sites 
(A. and B.) and in the oropharynx (C. and D.)
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5. DISCUSSION 
We analyzed the tumor samples of 247 consecutive patients living in North-East Italy 
affected by head and neck squamous cell carcinoma in a prospective study. The correct 
definition of the causal role of HPV in these tumors has clinical implications. The 
active involvement of the virus was investigated by analyzing several markers (viral 
load, viral transcripts, regulation of p16INK4a and pRb, presence of oncoE6 protein, and 
HPV seromarkers).  
 
 
5.1 HPV DNA prevalence  
In the present study, the overall HPV DNA prevalence was 8.5% (21/247). Oropharynx 
was the site with the highest frequency of HPV DNA positive cases (27%). HPV DNA 
prevalence in the other head and neck anatomic sites was 8% in the hypopharynx, 2% 
in the oral cavity and 1% in the larynx.  
 
A systematic review published by Kreimer et al.107 reported a global  HPV DNA 
prevalence of 25.9% in HNSCC, much higher compared to what obtained from our data 
(overall HPV DNA prevalence 8.5%). Although the highest incidence of  head and 
neck tumors is recorded in northern Italian regions (compared to the southern regions 
and the islands), the low HPV prevalence data obtained are probably due to the actual 
main role of tobacco smoking and alcohol consumption in this area 106, 177 and /or a 
lower exposure to the virus potentially due to different sexual behavior. 
 
Although, the prevalence of HPV-associated HNSCC in the different geographic areas 
varies greatly, oropharynx is always the predilected site. The literature reports a wide-
ranged prevalence of HPV in the oropharyngeal tumors (OPSCC) between 20% up to 
93%.  
In North America the HPV positive OPSCC proportion ranges between 47% - 70% 107, 
178
, while for Asia it was estimated to be 47.5% 107. 
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Among the Northern European countries, Sweden was the country with the highest 
HPV DNA incidence (93%) in the tonsils 109. The Netherlands appears to have the 
lowest HPV proportion in the oropharyngeal tumors, about 20% from 1997-2002, 
however showed a 10% increase (overall 30%) in the last years (2010) 179, 180. Spain, a 
South European country, reported an HPV incidence of 29% in the OPSCC 181, 
indicating a similar HPV behavior like in the population in study. 
 
In our series, the most prevalent type found was HPV16 (95%), and one case was 
infected by type 58. In this study for the first time causal involvement of HPV58 in a 
HNSCC has been documented by a broad variety of viral and cellular markers of HPV 
transformation 182. 
In cervical carcinoma, worldwide, HPV type 16 is the most prevalent type (61%), the 
other carcinogenic types, i.e. HPV18, 31, 33, 35, 39, 45, 51, 52, 56, 58 and 59 (here 
referred to as non-HPV16 types) are responsible for approximately another 33% of 
CxCa, with HPV58 specifically accounting for 2% of CxCa 183. 
Differently from CxCa, HPV-associated HNSCC are caused almost exclusively by 
infection with type 16 (89-97%) and the DNA of the other non-HPV16 types has been 
rarely detected 107, 157, 184. A recent metanalysis of HPV DNA prevalence in head and 
neck cancers (Ndiaye C, Alemany L et al., in preparation) identified 11 (0.8%) HPV58 
DNA positives among a total of 1466 HPV DNA positive oropharyngeal cancer cases 
that had been analyzed for presence of HPV58 DNA.  
 
The geographical heterogeneity might be the result of differences in the frequency of 
the different risk factors, HPV biology and study characteristics.  
HPV presence in the oral mucosa in the north Italian regions is very low (1%).  A study 
conducted in 81 healthy patients living in North Italy, detected a single HPV DNA 
positive case for type 90 185. Also, a systematic review of the literature (18 studies 
published between 1997-2009) reported a prevalence of any HPV infection of 4.5%. 
HPV16 prevalence was 1.3%, the highest prevalence among the other hr-HPV types 
detected 116. In the US population prevalence of oral HPV in the healthy population (in 
2009-2010) appeared to be higher (6.9%), however HPV16 was the most common hr 
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HPV type found (1%) 186. The other risk factors, tobacco smoking and alcohol 
consumption are relevantly present in our population.  
Differences in composition of the patient series constitutes another source of 
variability; studies with a small sample size have a low statistical power, 
misclassification of the head and neck anatomic sites can influence the relative HPV 
prevalence in the subsites. Moreover, poor quality of analyzed specimens and the HPV 
detection methods can substantially alter the results.  
In our study, fresh frozen specimens were analyzed by two different methods to 
genotype HPV, the MY09/11-RFLP and the BSGP5+/6+ -PCR/MPG. Both methods 
target conserved sequences of the L1 region of HPV and amplify 49 and 51 types, 
respectively. The BSGP5+/6+ -PCR/MPG is a multiplex assay which homogeneously 
amplify all the included mucosal types. The detection limit for each of the 51 HPV 
types ranges from 10-1000 copies, thus detecting HPV types also when present with  a 
low viral load. MY09/11 primers amplify a 450 bp sequence, and have an 
approximately 10-fold lower sensitivity 128.  
A group of samples were doubly tested. We observed a high concordance among the 
two methods (overall concordance 99/102, 97%). Three cases were discordant, 2 were 
identified as HPV DNA type 16 positive only by BSGP5+/6+ -PCR/MPG and 
considered positive as a result of its higher analytical sensitivity, and 1 was identified 
as positive by the MY09/11-RFLP method only and was considered as false positive.  
It is now well established that DNA alone is not sufficient to determine HPV causality 
in head and neck tumors 130, 157. 
 
To elucidate the biological role of the HPV DNA sequences found in the tumors, the 
study included other markers that combined with HPV DNA status provided the 
necessary information to identify the fraction of tumors with active HPV involvement. 
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5.2 HPV RNA prevalence  
The gold standard to demonstrate the viral activity and the transforming capacity of 
HPV in the tissues is considered to be the detection of E6 and/or E7 viral mRNA, the 
two relevant oncoproteins. 
An ultra-short amplimer, type and splice-site specific, E6*I mRNA RT-PCR assay, was 
used on fresh-frozen or FFPE samples. The analysis was performed on 18 HPV DNA 
positive (for 3 cases no specimens were available) and 27 HPV DNA negative 
specimens.  
Overall, in 14 out of 18 (78%) HPV DNA positive tumors the viral transcripts were 
detected; 13 were positive for type 16 and one for HPV58, confirming the DNA HPV 
type detection. None of the HPV DNA negative samples showed positivity for HPV16 
viral transcripts. The proportion of HPV DNA cases showing active viral transcription 
(78%) is higher compared to other studies where the HPV transformed proportion was 
lower (40% and 50%) 157, 187. 
 
Viral transcripts analysis showed a reduced prevalence (6%) compared to that found by 
DNA-based (8.5%) methods.  Thus, HPV DNA prevalences reported in previous 
studies 107, 184, 188, 189 might have been overestimated in previously reported studies. The 
HPV RNA prevalence, like the DNA data, indicated oropharynx as the site with the 
highest HPV positivity (20%). In the other anatomic sites, differently from the DNA 
data, the oral cavity showed higher prevalence than the hypopharynx (1% and 0%, 
respectively), while the larynx mantained the same value (1%). However, due to the 
low number of the HPV DNA positive cases in each of the non-oropharyngeal sites 
analyzed the change of HPV RNA positivity does not provide any significant 
information. 
 
Good quality of RNA is often difficult to obtain especially when no fresh frozen 
material is available. Therefore, there is a need to find other direct and/or indirect 
markers that can be alternatively used to define the truly HPV-associated tumors. 
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5.3 Additional viral and cellular markers in relation to the HPV DNA status 
and definition of the HPV driven group. 
Viral load was measured in HPV DNA positive samples (17 cases) by an ultra-short 
quantitative PCR (HPV16 qPCR) and the quantitative BSGP5+/6+ -PCR/MPG51. The 
majority of the samples (82%, 14/17) showed a high viral load (> 0.5 genome viral 
copies per cell), 18% (3/17) of the samples showed a negative viral load. 
Comparing viral load and HPV RNA positivity, 13 cases were identified as RNA+ and 
high viral load, 3 cases as RNA negative and negative viral load, while one case, that 
was RNA negative with high viral load showed discordance to this pattern. Our data 
showed a good concordance (93%, 13/14) between RNA expression and viral load and 
are in line with what published by Jung et al., where showed that 11/12 RNA positive 
samples had a high viral load 187. 
 
Expression of the HPVE6 oncoprotein increases the level of p16INK4a protein via a 
negative feedback mechanism, while the expression of the E7 protein leads to pRb 
degradation. Therefore, in tumors truly HPV-associated p16INK4a is up-regulated while 
pRb is down-regulated, making these 2 proteins of potential use as indirect markers. 
In our study, overall p16INK4a was up-regulated in 20% (10/52) while pRb was down-
regulated in 18% (7/47) of the tested samples. Relating the expression of p16INK4a and 
pRb cellular proteins (as single markers) to the HPV DNA positivity, 82% (9/11) of the 
cases showed  up-regulated p16INK4a and 54% (6/11) had down-regulated pRb.  
Among the HPVDNA+ cases, both markers could be evaluated in 10 cases; up-
regulated p16INK4a and down-regulated pRb was observed in 60% (6/10) of the cases 
(Table 2). 
In our series, p16INK4a expression (as a single marker) was a more suitable marker  
compared to pRb when combined with HPV DNA status as reported also in other 
studies 190. This correlation was particularly good for tumors occurring in the 
oropharynx 130, 191, 192 and larynx 155. Nevertheless, there is still a percentage of 
oropharyngeal cases that are positive for p16INK4a immunohistochemistry but lack HPV 
DNA; these cases were shown to have a molecular profile typical of non-HPV 
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associated tumors 180. Also,  p16INK4a was reported to be a non suitable marker for the 
hypopharynx 193 and the oral cavity 194.  
When combined, the up-regulation of p16INK4a with the down-regulation of pRb did not 
show a strong correlation with HPV DNA+ and RNA+ (60%). 
 
Presence of the E6 protein in cervical carcinoma 195 could represent a good marker for 
HPV-driven carcinoma, and it also represents a potential target for therapy 196. In the 
present study, the presence of HPV16 and HPV18 E6 protein was investigated by the 
commercial assay OncoE6 (Arbor Vita Corporation) in 7 HPV16 DNA positive tumors. 
Although the number of samples was low, we observed an excellent concordance 
(100%, 7/7) between the expression of the E6 protein and HPV DNA and RNA 
positivity, high viral load and overexpression of p16INK4a. 
In a larger set of samples, the sensitivity and specificity of the OncoE6 test were 97% 
and 96%, respectively, with an excellent agreement with the HPV RNA status (K= 
0.94) (Holzinger et al. manuscript in preparation).  
 
In an unselected subgroup (41%) of HN-patients we tested the seropositivity for 29 
HPV serological markers, i.e. antibodies to early and late proteins of the 7 most 
frequent hr-HPV types.  
HPV L1 antibodies are considered markers of past and present infection. HPV type 
concordant E6 and E7 double antibody positivity has been demonstrated to be highly 
associated and specific for invasive HPV-associated cancers with an extremely low 
prevalence of about 0.1% in tumor-free individuals 117 and to be strongly associated 
(odds ratios of 44 to 180) with invasive cancer of the cervix 197, the penis 198 and the 
upper aerodigestive tract 117, 175. 
Among the HPV proteins assessed, all the sera from the 7 patients with HPV-driven ( 
DNA+RNA+) tumors showed strong positive antibody reactions with HPVE6 and E7 
proteins. In contrast, none of the other sera (94) from patients with HPV DNA negative  
tumors resulted positive for both E6 and E7 for any of the HPV types tested. Also, in 
patients with HPV DNA+RNA+ HNSCC, seropositivity with early proteins frequently 
showed cross-reactions with the homologous proteins of the 6 other HPV types, most 
common for E7 (mean number of E7 proteins recognized 2.9) followed by E6 (mean 
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1.7). Patients with HPV-driven tumors also recognized more of the early proteins than 
those with HPV DNA- tumors. Type concordance of the strongest serological reaction 
to the individual proteins with HPV type by DNA was high. All 6 patients with 
HNSCC driven by HPV16 showed the strongest reactions with the E6 and E7 proteins 
of HPV16. The patient with the HPV58-driven tumor reacted strongest with E7 of 
HPV58 but the reaction with HPV33 E6 was stronger than that with HPV58 E6.  
The observed reactivity is probably due to the low number of divergent amino acids (< 
40 amino acids) present in the HPVE6 and E7 proteins (Michael K. diploma thesis 
2004). Also, a case-control studies reported a higher cross-reactivity for antibodies 
against the E7 (<5%) than the E6 (0.8%) proteins, probably due to technical reasons 175. 
 
One serum from a patient with a HPV16 DNA+ tumor for which no other molecular 
markers could be analyzed demonstrated strong antibody reactivities with all four early 
proteins of HPV16, suggestive for the presence of an HPV16-driven tumor. Another 
case was double positive with E6 and E1 of HPV16, even with the super-stringent cut-
off. Further analyses should be performed (HPV16 E6*I RNA and the cellular 
surrogate markers) to exclude false negative HPV genotyping result. 
 
One of the limitations of the serologic assays is the non site-specificity, therefore 
infections outside the head and neck region might influence the estimates. Also, not all 
the individuals exposed to HPV seroconvert 199 or maintain detectable antibody levels 
over time. Seroconversion could be missed due to waning of antibodies or host genetic 
background 200. HPV variants might, also, enhance a different immunogenicity 201. 
 
From our study and also in line with what is published, the double HPVE6 and E7 
seropositivity was the best marker identifying the HPVDNA+RNA+ cases related to 
the tumor, with a good sensitivity (100%) and specificity (99%).  
 
Based on the correlations found for each of the analyzed markers, we defined as HPV-
driven all the samples that showed HPV DNA and RNA positivity (14/18 cases), as 
well as the single case that could not be tested for RNA expression but was HPV DNA 
positive and seropositive for both oncoproteins E6 and E7. 
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5.4 Presence of the risk factors in the HPV DNA+ group and survival 
analysis 
Patients with HPV-associated tumors have been described to exhibit unique 
characteristics, including a younger age at diagnosis, less exposure to tobacco and 
alcohol, lower T-classification, higher N-classification and a better prognosis 191. In our 
HN-series, we did not observe in the HPV-positive group statistical significant 
differences related to age (68 years old in the HPV+ vs 65 years old in the HPV-), or 
smoking (48% never vs 28% current), or alcohol consumption (28% never vs 53% 
current), or tumor size T (52% T1-T1 size vs 48% T3-T4). The majority (76%) of the 
HPV-positive HN-cases had a nodal involvement.  
Among patients with all head and neck tumors, overall and progression free survival 
were not significantly better in the HPV-positive group compared to the HPV-negative 
one. 
 
Considering that the majority of the HPV-driven cases belong to the oropharynx we 
restricted the analyses to this anatomic site. 
Most of the HPV-driven patients were non smokers while most of the HPV negative 
one were smokers (p-value < 0.05). We could not demonstrate the same significance 
regarding the alcohol consumption (p-value > 0.05), even though the alcohol 
consumption was declared by a higher proportion of patients with HPV-related tumors. 
Statistical analyses for Overall Survival (OS) and Progression Free Survival (PFS) 
showed a trend of better survival in the HPV-driven group (p-value = 0.14 and 0.04, 
respectively). Still, the low number of the HPV-driven cases influenced the statistical 
power of all the performed analyses. 
 
 
5.6 Conclusions 
In the present study, in samples of patients affected by head and neck squamous cell 
carcinoma living in Northern Italy, collected from 2003-2012, a very low HPV 
prevalence was detected. Oropharynx was the predominant site for HPV infection. 
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We highlighted the importance of a better classification of the HPV-driven tumors by 
analyzing several markers, and a trend for a better survival of the HPV-driven group in 
the oropharyngeal site. 
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6. ABBREVIATIONS 
 
Abs Antibodies  
bp base pair 
bp base pairs  
BS broad-spectrum 
CT chemotherapy 
Cp crossing point  
Cy cyclin 
CKD cyclin-dependent kinase 
°C degree Celsius 
DAB 3,3'-Diaminobenzidine 
DNA  deoxyribonucleic acid 
E6AP E6-associated protein  
ER endoplasmic reticulum . 
EGF epidermal growth factor 
e.g. Exampli gratia 
ERK extracellular signal-regulated kinase  
FFPE formalin-fixed paraffin-embedded 
fl full-length  
GST glutathione S-transferase  
HNC Head and neck cancer 
HNSCC head and neck squamous cell carcinoma 
H&E hematoxilyn and eosin staining 
HPSGs heparin sulfate proteoglycans  
hr- high-risk types 
HDACs histone deacetylases  
 HPV Human Papillomavirus 
HC2 Hybrid Capture 2 
i.e. id est 
IHC immunohistochemistry 
IARC International Agency for Research on Cancer  
ICTV 
International Committee on Taxonomy of 
Viruses  
l liter 
LCR long control region  
lr- low-risk”  types 
MFI Median Fluorescence Intensity 
mRNA messenger-RNA 
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µg microgramm 
µl microliter 
mg milligram 
ml milliliter 
mmol millimolar 
min minute 
M Molar 
MPG Multiplex Papillomavirus Genotyping 
TEMED N,N,N’,N’-Tetramethylethylendiamine 
ng nanogram 
nm nanometers  
nt nucleotide  
ORF open reading frame  
OD Optical Density 
OSCC oropharyngeal squamous cell carcinoma 
OS Overall survival  
PV Papillomaviruses  
PC Phenol-Chloroform  
PE Phycoerythrin 
PCR Polymerase Chain Reaction 
PFS Progression-free survival  
qPCR quantitative real-time PCR  
RT radiotherapy  
RPA replication protein A 
RFLP restriction fragment length polymorphism 
pRB Retinoblastoma tumour  
RT-PCR reverse transcription  
RNA ribonucleic acid 
SDS sodio dodecyl solfate 
URR upstream regulatory region 
vs versus 
VL viral load 
VLP virus-like capsid particle  
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